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A B S T R A C T
Background
Progressive disseminated histoplasmosis (PDH) is a serious fungal infection that aFects people living with HIV. The best way to treat the
condition is unclear.
Objectives
We assessed evidence in three areas of equipoise.
1. Induction. To compare eFicacy and safety of initial therapy with liposomal amphotericin B versus initial therapy with alternative
antifungals.
2. Maintenance. To compare eFicacy and safety of maintenance therapy with 12 months of oral antifungal treatment with shorter
durations of maintenance therapy.
3. Antiretroviral therapy (ART). To compare the outcomes of early initiation versus delayed initiation of ART.
Search methods
We searched the Cochrane Infectious Diseases Group Specialized Register; Cochrane CENTRAL; MEDLINE (PubMed); Embase (Ovid); Science
Citation Index Expanded, Conference Proceedings Citation Index-Science, and BIOSIS Previews (all three in the Web of Science); the WHO
International Clinical Trials Registry Platform, ClinicalTrials.gov, and the ISRCTN registry, all up to 20 March 2020.
Selection criteria
We evaluated studies assessing the use of liposomal amphotericin B and alternative antifungals for induction therapy; studies assessing
the duration of antifungals for maintenance therapy; and studies assessing the timing of ART. We included randomized controlled trials
(RCT), single-arm trials, prospective cohort studies, and single-arm cohort studies.
Data collection and analysis
Two review authors assessed eligibility and risk of bias, extracted data, and assessed certainty of evidence. We used the Cochrane 'Risk of
bias' tool to assess risk of bias in randomized studies, and ROBINS-I tool to assess risk of bias in non-randomized studies. We summarized
dichotomous outcomes using risk ratios (RRs), with 95% confidence intervals (CI).
Main results
We identified 17 individual studies. We judged eight studies to be at critical risk of bias, and removed these from the analysis.
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1. Induction
We found one RCT which compared liposomal amphotericin B to deoxycholate amphotericin B. Compared to deoxycholate amphotericin
B, liposomal amphotericin B may have higher clinical success rates (RR 1.46, 95% CI 1.01 to 2.11; 1 study, 80 participants; low-certainty
evidence). Compared to deoxycholate amphotericin B, liposomal amphotericin B has lower rates of nephrotoxicity (RR 0.25, 95% CI 0.09 to
0.67; 1 study, 77 participants; high-certainty evidence). We found very low-certainty evidence to inform comparisons between amphotericin
B formulations and azoles for induction therapy.
2. Maintenance
We found no eligible study that compared less than 12 months of oral antifungal treatment to 12 months or greater for maintenance
therapy.
For both induction and maintenance, fluconazole performed poorly in comparison to other azoles.
3. ART
We found one study, in which one out of seven participants in the 'early' arm and none of the three participants in the 'late' arm died.
Authors' conclusions
Liposomal amphotericin B appears to be a better choice compared to deoxycholate amphotericin B for treating PDH in people with HIV;
and fluconazole performed poorly compared to other azoles. Other treatment choices for induction, maintenance, and when to start ART
have no evidence, or very low certainty evidence. PDH needs prospective comparative trials to help inform clinical decisions.
P L A I N   L A N G U A G E   S U M M A R Y
How best to treat progressive disseminated histoplasmosis in people with HIV
What was the aim of this review?
The aim of this Cochrane Review was to investigate some treatment dilemmas with progressive disseminated histoplasmosis in people
living with HIV. We collected and analysed all relevant studies to answer this question and found 17 studies.
Key messages
Liposomal amphotericin B may improve clinical success compared to deoxycholate amphotericin B when starting treatment.
Liposomal amphotericin B results in less kidney damage compared to deoxycholate amphotericin B when starting treatment.
We are unsure how long people should stay on treatment aLer they have successfully completed the starting stage. We are unsure at what
time during treatment of the fungal infection it is best to start treatment to fight the HIV virus.
What was studied in this review?
Histoplasmosis is an infection caused by inhaling a fungus called Histoplasma. The most severe form of histoplasmosis is called progressive
disseminated histoplasmosis, in which the infection spreads from the lungs to other organs. It is life-threatening for people with advanced
HIV.
The treatment of progressive disseminated histoplasmosis starts with 'induction', in which medicines are started to rapidly attack the
fungus. The next phase is called 'maintenance', in which medicines are used to prevent the fungus taking hold again. During treatment of
the fungus, antiretroviral medicines are started to fight the HIV virus.
We wanted to find out the best induction treatment, if maintenance could be for less than one year, and when was the best time to start
antiretroviral medicines.
What are the main results of the review?
We found 17 studies. We removed eight from the review as they did not include important measurements that might change results. These
included how severe the HIV infection was, or if the patients had other infections at the same time.
One study compared two forms of the same medicine for starting treatment of histoplasmosis, liposomal amphotericin B and deoxycholate
amphotericin B. It found that the more expensive liposomal form is less likely to cause kidney damage and may have higher clinical success
rates than the deoxycholate form.
None of the studies looked at whether maintenance could be less than one year. Two studies looked a antiretroviral medicines, but we do
not know when it is best to start them.
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How up to date is the review?
We searched for studies that had been published up to 20 March 2020.
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Summary of findings 1.   Induction: liposomal amphotericin compared with amphotericin deoxycholate
Liposomal amphotericin compared with amphotericin deoxycholate for induction therapy of progressive disseminated histoplasmosis
Patient or population: adults with HIV and progressive disseminated histoplasmosis
Settings: endemic areas
Intervention: induction therapy with liposomal amphotericin B
Comparison: amphotericin B deoxycholate
Illustrative comparative risks*
(95% CI)
Assumed risk Corresponding
risk
Outcomes
dAmB lAmB
Relative effect
(95% CI)
Number of
participants
(studies)
Certainty of
the evidence
(GRADE)
Comments
Clinical suc-
cess
560 per 1000 818 per 1000
(566 to 1000)
RR 1.46
(1.01 to 2.11)
80
(1 study)
⊕⊕⊝⊝
Low a
Compared to dAmB, lAmB may have higher clinical success
rates.
Death 125 per 1000 19 per 1000
(3 to 173)
RR 0.15
(0.02 to 1.38)
77
(1 study)
⊕⊕⊝⊝
Low b
Treatment with lAmB may result in lower mortality than
treatment with dAmB.
Safety out-
comes:
nephrotoxici-
ty
375 per 1000 94 per 1000
(34 to 251)
RR 0.25
(0.09 to 0.67)
77
(1 study)
⊕⊕⊕⊕
High
Treatment with lAmB resulted in lower rates of nephrotox-
icity compared to treatment with dAmB; this was support-
ed by findings of a Cochrane Review which reported moder-
ate-certainty evidence (Botero Aguirre 2015).
Safety out-
comes: drug
discontinua-
tion
83 per 1000 19 per 1000
(2 to 198)
RR 0.23
(0.02 to 2.38)
77
(1 study)
⊕⊝⊝⊝
Very low c
We do not know if treatment with lAmB leads to fewer treat-
ment discontinuations than dAmB.
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the as-
sumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; dAmB: deoxycholate amphotericin B; lAmB: liposomal amphotericin B; RR: risk ratio.
GRADE Working Group grades of evidence
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High certainty: further research is very unlikely to change our confidence in the estimate of effect.
Moderate certainty: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low certainty: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low certainty: we are very uncertain about the estimate.
aDowngraded two levels for very serious imprecision: the CI met the line of no eFect and was based on very few events (73 participants, 1 randomized controlled trial).
bDowngraded two levels for very serious imprecision: the CIs were wide and crossed the line of no eFect.
cDowngraded one level for serious risk of bias (due to unclear reporting criteria) and two levels for very serious imprecision (the CIs were wide and crossed the line of no eFect).
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B A C K G R O U N D
Description of the condition
Progressive disseminated histoplasmosis (PDH) is an important
infectious disease among people living with HIV. PDH is one of
the endemic mycoses, meaning a fungal infection localized to a
specific region. It is caused by two human pathogens, Histoplasma
capsulatum var. capsulatum (in the Americas) and Histoplasma
capsulatum var. duboisii (in Africa). It causes severe morbidity and
carries a risk of mortality of over 60% (Adenis 2014; Cano-Torres
2019). H capsulatum var. capsulatum has historically been thought
of as predominantly eFecting the Americas, but there is evidence of
a wider global distribution (Baker 2019).
The diagnosis of PDH in people living with HIV is usually made
based on:
• risk factors for the disease (advanced HIV);• clinical manifestations consistent with disseminated
histoplasmosis, such as fever, fatigue, weight loss, and
hepatosplenomegaly;• histoplasma antigen assays;• microscopic demonstration or isolation of Histoplasma from
extrapulmonary sites; due to slow growth, isolation is likely to
be too slow to allow diagnosis.
Description of the intervention
The current standard of care for PDH is typically based on Infectious
Diseases Society of America 2007 guidelines (Wheat 2007). This
guideline recommends:
• for moderately severe to severe disease, liposomal
amphotericin B (3.0 mg/kg daily for 1 to 2 weeks), followed by
oral itraconazole (200 mg 3 times daily for 3 days and then 200
mg twice daily for a total of at least 12 months);• for mild-to-moderate disease, itraconazole (200 mg 3 times daily
for 3 days), and then twice daily for at least 12 months.
Alongside treatment of PDH, HIV is treated with antiretroviral
therapy (ART). Commencing ART might rapidly restore immune
function. This may cause an excessive inflammatory response
known as immune reconstitution inflammatory syndrome (IRIS)
(Melzani 2020).
How the intervention might work
Azoles inhibit biosynthesis of ergosterol, which is essential in fungal
cell membranes. Itraconazole, voriconazole, and posiconazole are
thought to be fungicidal for histoplasma, but fluconazole is thought
to have fungistatic activity only. Polyenes, such as amphotericin B,
bind to fungal membrane sterols and disrupt cell membranes. They
are thought to have fungicidal activity. Non-randomized trial data
from animal studies suggest that near maximal antifungal activity
with amphotericin B occurs within three days, which has led to
interest in shorter courses in treatment of other mycoses, such as
cryptococcal meningitis (Tenforde 2018).
Why it is important to do this review
Currently available guidelines for management of PDH date from
2007. These were designed for use by clinicians in the USA, a
high-resource country. The advent of widespread availability of
ART internationally has changed treatment paradigms for HIV. In
resource-limited settings, there is interest in revisiting the optimal
treatment options for PDH. This review summarizes available
evidence, and in particular we aimed to understand if new evidence
could inform updated international guidelines on PDH.
O B J E C T I V E S
1. Induction. To compare eFicacy and safety of initial therapy with
liposomal amphotericin B versus initial therapy with alternative
antifungals.
2. Maintenance. To compare eFicacy and safety of maintenance
therapy with 12 months of oral antifungal treatment with shorter
durations of maintenance therapy. (Please note, itraconazole is a
preferred oral antifungal agent, see results.)
3. Antiretroviral therapy (ART). To compare the outcomes of early
initiation of ART versus delayed initiation of ART.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We planned to synthesize the study types in order of priority. At
each stage, if we found a suFicient number of studies to allow a
high-certainty synthesis, we did not intend to progress further. As
we did not find suFicient evidence to allow high-certainty synthesis,
our review includes the following study types:
• randomized controlled trials (RCTs);• quasi-RCTs/non-RCTs;• prospective cohort studies;• retrospective cohort studies;• single arm cohort studies.
We excluded case reports and case series.
Types of participants
HIV-positive children, adolescents, and adults with a clinical
diagnosis of PDH.
Types of interventions
We aimed to make the following comparisons.
 
Objective Intervention Comparisons
1. Induction Liposomal amphotericin B (3.0 mg/kg daily) for 1–2
weeks
Lipid complex amphotericin B
Deoxycholate amphotericin B
Other antifungal agents
Treating progressive disseminated histoplasmosis in people living with HIV (Review)
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2. Maintenance Oral antifungal treatment for < 12 months Oral antifungal treatment for ≥ 12 months
3. ART Early initiation (within 4 weeks of commencing anti-
fungal therapy)
Delayed initiation (> 4 weeks after starting antifungal
treatment)
 
Types of outcome measures
We collected data on key outcomes, as summarized in the table
below.
 
Objective Efficacy outcomes of interest Safety outcomes of interest
1. Induction Clinical failure at or before study end
Laboratory failure at or before study end
Toxicity
Early discontinuation
2. Maintenance Relapse of histoplasmosis at 12 months, or other clinically important time
points
All-cause mortality at 12 months
Toxicity
Early discontinuation
3. ART Incidence of immune reconstitution inflammatory syndrome
Viral failure
Toxicity
Early discontinuation
 
Where possible, we collected dichotomous and time-to-event data
for relevant outcomes. We also collected data on mortality, and
severe adverse events, including type and frequency.
Search methods for identification of studies
Electronic searches
We developed our search strategy with the assistance of the
Information Specialist, Vittoria Lutje. We searched the following
databases on 20 March 2020 using the search terms and
strategy described in Appendix 1: Cochrane Infectious Diseases
Group Specialized Register; Central Register of Controlled Trials
(CENTRAL; 2020, Issue 3, published in the Cochrane Library);
MEDLINE (PubMed, from 1966); Embase (Ovid, from 1947); Science
Citation Index Expanded (SCI-EXPANDED, from 1900), Conference
Proceedings Citation Index-Science (CPCI-S, from 1900), and BIOSIS
Previews (from 1926) (all three using the Web of Science platform).
We also searched the World Health Organization International
Clinical Trials Registry Platform (www.who.int/ictrp/search/en/),
ClinicalTrials.gov (clinicaltrials.gov/), and the ISRCTN registry
(www.isrctn.com/) to identify ongoing studies.
Searching other resources
We examined reference lists of relevant studies and reviews.
Data collection and analysis
Selection of studies
Two review authors (MM and PH) screened the titles and abstracts
of the search results to determine eligibility using Covidence
(www.covidence.org/). We did not perform double screening as we
prepared the review rapidly to inform a guidelines meeting. We
each assessed a random sample of the other author's screening.
There were no disagreements. Both review authors screened
the full texts of potentially eligible studies, and resolved any
disagreement by discussion. At the time of full-text screening, we
categorized the studies by study design.
Data extraction and management
One review author (PH) extracted data, and one review author (MM)
reviewed all data extraction to ensure accuracy.
Assessment of risk of bias in included studies
For each included study, both review authors performed a
risk of bias assessment resolving any disagreements through
discussion. We used the Cochrane 'Risk of bias' tool for RCTs.
For non-randomized studies, we used the Risk of Bias In
Non-Randomized Studies of Interventions (ROBINS-I) tool. We
developed a theoretical target study and assessed each non-
randomized study across up to seven domains. Each assessment
was discontinued if a domain was deemed to be at critical
risk of bias. Each outcome was assessed. We identified relevant
confounding factors through investigation of the literature and in
discussion with expert clinicians. These a priori factors included
severity of disease (histoplasmosis and CD4 count); time to
treatment; and, for objectives 2 and 3, adherence to ART/
maintenance therapy for histoplasmosis.
Data synthesis
Narrative synthesis
We followed narrative synthesis methodology (Popay 2006). Within
this synthesis, we organized findings from included studies to
describe patterns across the studies in terms of the:
Treating progressive disseminated histoplasmosis in people living with HIV (Review)
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• direction of eFects;• size of eFects.
We calculated 95% confidence intervals (CI) for binomial
proportions. We calculated 95% CIs for risk ratios (RR) using Review
Manager 5 (Review Manager 2014). Studies assessed as at critical
risk of bias were excluded from narrative synthesis.
Quantitative synthesis
We did not identify trials that were suFiciently similar in design or
outcomes to allow a meaningful meta-analysis of outcome data.
Therefore, we have not performed quantitative synthesis.
Exploring relationships in the data
We planned to explore relationships to consider the factors that
might explain any diFerences in direction and size of eFect across
the included studies. For data included in narrative synthesis,
we explored relationships using textual descriptions of key study
elements (see Characteristics of included studies table), groupings
and clusters of similar studies, and presentation of findings in
tabulated form.
Assessing the certainty of our conclusions
We planned to present adapted GRADE tables to summarize the
certainty of our findings for each outcome. As we did not find
good evidence to answer all objectives, we presented a GRADE
table for outcomes relevant to 'Objective 1. Induction' detailing
certainty of findings. We could not include any studies to answer
'Objective 2. Maintenance', so presented a narrative summary of
indirect evidence in the body of the review only. We presented an
additional summary table for 'Objective 3. ART'.
R E S U L T S
Description of studies
Results of the search
We retrieved 1259 results from our electronic search. ALer title and
abstract screening, we identified 206 reports for full-text screening.
Following full-text screening, we identified 16 individual studies
which were relevant to the review. These included:
• two RCTs (ACTG-A5164, 2009; Johnson 2002);• four single arm trials (ACTG084, 1992; ACTG120, 1992; ACTG174,
1994; McKinsey 1989);• four prospective cohort studies (Baddley 2008; Couppié 2004;
Goldman 2004; Ramdial 2002);• six retrospective cohort studies (Luckett 2015; Mootsikapun
2006; Myint 2014; Negroni 2017; Norris 1994; Pietrobon 2004).
We have shown the results of our search in Figure 1.
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Figure 1.   Review flow diagram.
 
We found one additional unpublished retrospective cohort study
via correspondence with authors (Melzani 2020).
Therefore, there were 17 individual studies. We excluded eight of
these studies from analysis as we assessed them to be at critical
risk of bias using ROBINS-I methodology (Table 1). We listed these
below.
Included studies
1. Induction
From our search, the studies that gave information about relevant
outcomes for induction therapies included:
• one RCT (Johnson 2002);• two single arm trials (ACTG120, 1992; ACTG174, 1994);• one retrospective cohort study (Luckett 2015).
The following studies were excluded from narrative synthesis as
they were at critical risk of bias using ROBINS-I methodology.
• one single arm trial (McKinsey 1989);• two prospective cohort studies (Couppié 2004; Ramdial 2002).
2. Maintenance
From our search, the studies that gave information about relevant
outcomes for maintenance therapies included:
• three single arm trials (ACTG084, 1992; ACTG120, 1992; ACTG174,
1994);• one prospective cohort study (Goldman 2004);• one retrospective cohort study (Mootsikapun 2006).
The following studies were excluded from narrative synthesis as
they were at critical risk of bias using ROBINS-I methodology:
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• one single arm trial (McKinsey 1989);• one prospective cohort study (Baddley 2008);• four retrospective cohort studies (Myint 2014; Negroni 2017;
Norris 1994; Pietrobon 2004).
3. ART
We found one RCT which helped inform decisions regarding ART
(ACTG-A5164, 2009). We included Melzani 2020 in a narrative
synthesis as it provided evidence of baseline risk, but could not
directly inform the objective.
Excluded studies
We excluded 186 studies (including an RCT, single arm trials,
prospective cohort studies, and retrospective cohort studies) aLer
full-text review. In the majority of cases, we were unable to extract
relevant data from the study reports. We reported reasons for
exclusion for a sample of 34 references in the Characteristics of
excluded studies table.
Risk of bias in included studies
For the two randomized studies, risk of bias was low (Johnson 2002
shown in Table 2; ACTG-A5164, 2009 shown in Table 3). These are
summarized in Figure 2.
 
Treating progressive disseminated histoplasmosis in people living with HIV (Review)
Copyright © 2020 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
10
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Figure 2.   Risk of bias summary: review authors' judgements about each risk of bias item for each included
randomized study.
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For the remaining 15 non-randomized studies, we assessed eight
to be at critical risk of bias using ROBINS-I, and excluded these
from synthesis as described above (Table 1). The remaining seven
non-randomized studies were at serious risk of bias using ROBINS-
I (Table 4). One study was at critical risk of bias for the relapse
outcome, and serious risk of bias for the mortality outcome
(Pietrobon 2004). We excluded this study from synthesis as the
mortality outcome did not suFiciently inform the objective.
Risk of bias was low in both included randomized studies (Table
2; Table 3; Figure 2). Eight non-randomized studies were at critical
risk of bias and eight at serious risk of bias overall using ROBINS-I.
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Details on assessment by outcome are provided in Table 1 and Table
4. Detailed domain assessments are available in Appendix 2.
EAects of interventions
See: Summary of findings 1 Induction: liposomal amphotericin
compared with amphotericin deoxycholate
1. Induction therapy for progressive disseminated
histoplasmosis
Liposomal amphotericin B compared to deoxycholate
amphotericin B
One RCT compared liposomal amphotericin B and deoxycholate
amphotericin B (Johnson 2002). There was greater treatment
success with liposomal amphotericin B compared to deoxycholate
amphotericin B (RR 1.46, 95% CI 1.01 to 2.11; 1 trial, 80 participants;
Analysis 1.1). There were three deaths in the deoxycholate
amphotericin B arm and one death in the liposomal amphotericin
B arm (RR 0.15, 95% CI 0.02 to 1.38; 1 trial, 77 participants; Analysis
1.2). There were lower rates of nephrotoxicity (defined as creatinine
greater than twice the upper limit of normal) with liposomal
amphotericin B than with deoxycholate amphotericin B (RR 0.25,
95% CI 0.09 to 0.67; 1 trial, 77 participants; Analysis 1.3). The authors
did not report other safety data, including frequencies of commonly
reported toxicities such as anaemia.
Liposomal amphotericin B compared to other antifungals
No RCTs compared liposomal amphotericin B to other antifungals.
One retrospective cohort study compared all forms of amphotericin
B to triazole therapy (including itraconazole, posaconazole, and
voriconazole) (Luckett 2015). Treatment success for triazoles was
83% (95% CI 62% to 95%). The report did not disaggregate data by
disease severity, but reported that across the study (which included
people who were immunocompromised for reasons other than HIV
infection), frequency of triazole failure was similar among people
with severe infection compared with those with mild-to-moderate
infection.
Deoxycholate amphotericin B compared to other antifungals
No study compared deoxycholate amphotericin B to other
antifungals.
Treatment success rates for other antifungals
In the absence of comparative studies, we reported treatment
success rates for antifungal agents (see 'Narrative results table 1').
Itraconazole
One single arm trial of itraconazole in mild-to-moderate PDH
reported a treatment success rate of 85% (95% CI 73% to 93%; 1
study, 50/59 participants) at a dose of 300 mg twice daily for three
days then 200 mg twice daily for 12 weeks (ACTG120, 1992).
Fluconazole
One single arm trial of fluconazole reported a treatment success
rate of 74% (95% CI 59% to 85%; 1 study, 36 successes of 49
participants), at a dose of 1600 mg on day one, then 800 mg once
daily for 12 weeks (ACTG174, 1994). This study initially reported a
treatment success rate of 80% (95% CI 56% to 94%; 16 successes
of 20 participants) for fluconazole 1600 mg on day one followed
by 600 mg once daily for eight weeks. However, the protocol
was intensified when relapse was subsequently observed in 6/16
participants (37.5%, 95% CI 15% to 64%).
Narrative results: table 1: induction therapy
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Study Method Partici-
pants
Interventions Primary out-
come(s)
Setting Disease
severity
Overall
risk of
bias
Narrative of efficacy
findings (95% CIs)
Narrative of safety find-
ings
ACTG120,
1992
Single
arm trial
59 with
PDH
ITRA 300 mg BD for 3
days then 200 mg BD
for 12 weeks
"Response to
therapy"
Death
USA Mild to
moder-
ate
Serious Clinical success:
50/59 participants
85% (73% to 93%)
Death:
1/59
2/59 participants with-
drew due to adverse
events, and responded to
AmB.
ACTG174,
1994
Single
arm trial
49 with
PDH
Initial protocol
FCN 1200 mg, then
600 mg OD for 8
weeks
Revised protocol
FCN 1200 mg, then
80 mg OD for 8 weeks
"Treatment
response"
USA Mild to
moder-
ate
Serious Clinical success:
36/49 participants.
74% (59% to 85%)
Revised protocol
2 discontinuations due to
toxicity, unclear if induc-
tion or maintenance.
Johnson
2002
RCT 81 with
PDH
lAmB (55 partici-
pants)
dAmB (26 partici-
pants)
Efficacy:
"Clinical suc-
cess"
Safety: early
discontinua-
tion
USA Moder-
ate to se-
vere
Low Clinical success:
lAmB: 82% (69% to 91%)
45/55 participants.
dAmB: 56% (37% to 76%)
14/25 participants.
RR 1.46
(1.01 to 2.11)
Death:
lAmB: 1/53 (2%)
dAmB: 3/24 (13%)
RR 0.15
(0.02 to 1.38)
Early discontinuation:
1/53 (2%) with lAmB vs
2/24 (8%) with dAmB
RR 0.23
(95% CI 0.02 to 2.38)
Nephrotoxicity: 5/53
(9%) with lAmB vs 9/24
(37%) with dAmB
RR 0.25
(95% CI 0.09 to 0.67)
Of note, authors did not
report specific data in re-
lation to other common-
ly recognized adverse ef-
fects, including anaemia.
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Luckett
2015
Retro-
spective
cohort
study
56 with
HIV and
PDH
ITRA/VORI/POSA
AmB
Death
(90-day histo-
plasmosis-re-
lated)
Triazole fail-
ure
USA Mild to
severe
Serious Death
5/56 participants.
Not reported by treatment
regimen.
Clinical success:
triazole induction success-
ful in 20/24 participants
83% (62% to 95%)
No safety issues reported.
AmB: amphotericin B; BD: twice daily; CI: confidence interval; dAmB: deoxycholate amphotericin B; FCN: fluconazole; ITRA: itraconazole; IAmB: liposomal amphotericin
B; n: number of participants; OD: once daily; PDH: progressive disseminated histoplasmosis; POSA: posaconazole; RCT: randomized controlled trial; RR: risk ratio; VORI:
voriconazole.
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2. Maintenance therapy
Less than 12 months of oral itraconazole compared to 12 months
or greater of oral itraconazole
No included study compared less than 12 months of oral
itraconazole and 12 months or greater of oral itraconazole.
Continuation of antifungals versus discontinuation of
antifungals
This result is summarized in Table 5.
One prospective single-arm cohort study followed a cohort of
participants who discontinued antifungal therapy aLer at least 12
months, providing the participant had received at least six months
of ART and had achieved a CD4 count of 150 cells/μL or greater
(Goldman 2004). There were no relapses in 32 participants who
discontinued therapy aLer 12 months.
Treatment success rates for modalities of maintenance
therapies
'Narrative results table 2' indicates crude treatment success rates
for diFerent maintenance therapies used in studies.
Itraconazole
Two single arm trials reported low relapse rates of approximately
0.5% with itraconazole (ACTG084, 1992; ACTG120, 1992).
Fluconazole
One single arm trial was discontinued early due to higher relapse
rates (11/36 participants; 30%, 95% CI 16% to 48%) (ACTG174,
1994). This trial used 400 mg doses of fluconazole aLer induction
with fluconazole.
Narrative results table 2: maintenance therapy
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Study Method Partici-
pants
Interventions Prima-
ry out-
comes
Setting Disease
severity
Overall
risk of
bias
Narrative of efficacy findings Narra-
tive of
safety
findings
Studies assessing discontinuation of oral antifungals
Gold-
man
2004
Prospec-
tive co-
hort
study
(single
arm)
32 Discontinuation after > 12
months of ITRA/FCN/AmB
Relapse
after 1
year
USA ≥ 6 months
of ART.
CD4 count <
150 cells/μL
Serious No relapses after 12 months of dis-
continuation of antifungal therapy.
No safe-
ty issues
report-
ed.
Studies reporting outcomes of maintenance therapy regimens
ACTG084,
1992
Single
arm trial
42 (after
dAmB in-
duction)
ITRA 200 mg BD; continuous Relapse
Death
USA No ART
Median CD4
count 47
cells/μL
(35 partici-
pants)
Serious Relapse:
2/42 participants (0.5%, 95% CI
0.05% to 16%)
Median follow-up 98 weeks
Death:
1/42 deaths attributed to PDH
Treat-
ment
discon-
tinua-
tion in
1/42 par-
ticipants
Severe
or life-
threat-
ening
adverse
events
in 37/42
partic-
ipants,
attrib-
uted
mainly
to HIV in-
fection,
oppor-
tunis-
tic infec-
tions,
and ad-
verse ef-
fects of
other
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medica-
tions.
ACTG120,
1992
Single
arm trial
46 (of 59
enrolled)
ITRA 200 mg (26 participants)
ITRA 400 mg (18 participants)
ITRA 600 mg (2 participants)
4 participants remained on dos-
es > 200 mg.
Median duration 64 weeks
(range 7–120 weeks)
Relapse USA No ART
Median CD4
29 cells/µL
Serious Relapse:
2/46 participants
(0.4%, 95% CI 0.05% to 14%)
Median follow-up 87 weeks
Death:
1/46 deaths due to relapse
Treat-
ment
discon-
tinu-
ation
in 8/46
partici-
pants.
24/46
partic-
ipants
enrolled
known
to have
died, in-
cluding
discon-
tinua-
tions;
pre-ART.
ACTG174,
1994
Single
arm trial
49 with
PDH, 36
entered
mainte-
nance
therapy
FCN 400 mg Continuous
Median duration 30 weeks (ear-
ly termination of study)
Relapse USA No ART
Mild to se-
vere
Serious Relapse:
11/36 participants (30%, 95% CI
16% to 48%)
2 dis-
contin-
uations
due to
toxicity,
unclear
if induc-
tion or
mainte-
nance.
AmB: amphotericin B; ART: antiretroviral therapy; BD: twice daily; dAmB: deoxycholate amphotericin B; FCN: fluconazole; ITRA: itraconazole; n: number of participants;
PDH: progressive disseminated histoplasmosis.
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3. ART initiation
One trial compared early ART initiation to late ART initiation
in people with coexisting opportunistic infections (ACTG-A5164,
2009). There were 10/282 participants with a presumptive or
confirmed diagnosis of histoplasmosis. No diagnostic criteria were
given for histoplasmosis. One participant with histoplasmosis in
each trial arm developed IRIS. Both survived. One out of seven
participants in the early ART died by day 30. None of the three
participants with histoplasmosis in the delayed group died by day
30. This result is summarized in 'Narrative results table 3' and Table
6.
One additional study reported crude incidence rates of histoplasma
IRIS including paradoxical IRIS (flare-up of a previously treated
histoplasmosis) (Melzani 2020). This indicated an overall incidence
rate of 0.74 cases per 1000 person-years. This study does not
directly answer the objective of early versus deferred ART, but
provides an indication of baseline risk.
Narrative results table 3: antiretroviral initiation
Treating progressive disseminated histoplasmosis in people living with HIV (Review)
Copyright © 2020 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
18
Treating progressive dissem
inated histoplasm
osis in people living w
ith H
IV (Review
)
Copyright ©
 2020 The Authors. Cochrane Database of System
atic Review
s published by John W
iley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
19
Study Method Participants Interven-
tions
Outcomes Setting Disease
severity
Overall
risk of
bias
Narrative of findings
ACTG-
A5164,
2009
RCT 282, AIDS-re-
lated oppor-
tunist infec-
tions
10 people
with histo-
plasmosis
Early ART
(n 7)
Deferred
ART (n 3)
Primary: composite end-
point of death and HIV viral
load.
Safety: IRIS; lab adverse
events Grades 2–4; clinical
adverse events Grades 2-4.
USA,
South
Africa
Baseline
median
CD4 count
29 (IQR
10–55)
cells/μL
Low 1/7 participants with histoplasmosis
dies in the early ART group.
0/3 participants with histoplasmosis
died in the deferred ART group.
1/3 people with histoplasmosis in de-
ferred ART arm developed histoplas-
ma IRIS (day 47). IRIS aetiology: he-
patitis C. Survived.
1/7 people with histoplasmosis in ear-
ly ART arm developed hepatitis C IRIS
(day 14). IRIS aetiology: histoplasmo-
sis. Survived.
ART: antiretroviral therapy; IQR: interquartile range; IRIS: immune reconstitution inflammatory syndrome.
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D I S C U S S I O N
Summary of main results
For 'Objective 1. Induction' comparing liposomal amphotericin B
to other antifungals, four studies met the inclusion criteria: one
RCT with 81 participants and three non-randomized studies with
164 participants. We judged all three non-randomized studies at
serious risk of bias. Compared to deoxycholate amphotericin B,
liposomal amphotericin B may have higher clinical success rates
(low-certainty evidence), and has lower rates of nephrotoxicity
(high-certainty evidence). We do not know if all amphotericin B
formulations are more eFective than azoles for the induction phase
of management (very low-certainty evidence).
For 'Objective 2. Maintenance', comparing less than 12 months of
oral antifungal treatment to greater than 12 months, no studies met
the inclusion criteria.
For both objectives 1 and 2, fluconazole performed poorly in
comparison to other azoles in the single-arm trial which studied this
(ACTG174, 1994). No further trials were done as there was no longer
suFicient equipoise to justify this.
'Objective 3: ART' sought to compare early and delayed initiation of
ART. One RCT with 282 participants met the inclusion criteria. Only
10 participants had coexisting HIV and a presumptive or confirmed
diagnosis of PDH. By day 30, one of seven participants in the 'early'
arm and none of the three participants in the 'late' arm died. We
do not know the eFicacy and safety outcomes of early versus late
initiation of ART (very low-certainty evidence).
Overall completeness and applicability of evidence
The overall evidence was limited; therefore, we were unable to
address all the objectives of our review. Most studies were in
the USA and such findings may not be generalizable to low-
resource settings as availability of liposomal amphotericin B and
management of HIV may diFer. This aFects the external validity
of our review. There is insuFicient evidence to be confident that
azoles and other formulations of amphotericin are as eFective and
safe as liposomal amphotericin B in the induction phase of the
management of PDH in people living with HIV. Clinical practice may
be governed by availability. Current clinical practice would indicate
that shorter courses of maintenance therapy may be acceptable;
however, there is insuFicient evidence available to corroborate or
refute this practice. There is insuFicient evidence to be confident
of the safety of discontinuation of maintenance therapy before
12 months or the timing of ART. Overall, clinical practice tends to
favour early ART in most situations. The low rates of IRIS in the
single RCT do not present a signal that this practice is unsafe;
however, there is insuFicient evidence to confirm this. It seems that
people in resource-limited settings are doing what they are able to
do.
Certainty of the evidence
Overall, the certainty of the evidence for most outcomes was
low or very low. Non-randomized study designs predominate in
this area of research, many of which were critically compromised
by uncontrolled confounding. For the comparison of liposomal
amphotericin B to deoxycholate amphotericin B for induction
therapy, there was high-certainty evidence of lower rates of
nephrotoxicity (RR 0.25, 95% CI 0.09 to 0.67; 1 study, 77
participants). Evidence for clinical success for this comparison was
of low certainty due to very serious imprecision indicating that
further research is very likely to have an important impact on our
confidence in the estimate of eFect (RR 1.46, 95% CI 1.01 to 2.11;
1 study, 80 participants). For maintenance regimens, all six studies
were of a non-randomized design, at serious risk of bias, and they
could only provide low-certainty evidence.
Potential biases in the review process
To minimize the eFect of all domains of bias in the non-randomized
studies we presented only those at serious risk of bias. There is little
evidence available from populations outside the USA.
Agreements and disagreements with other studies or
reviews
Liposomal amphotericin B has previously been found to be
significantly safer than conventional amphotericin B with respect
to renal toxicity in PDH. One systematic review published in 2015
studying any invasive fungal infections reported an eFect size of
RR 0.49 (95% CI 0.40 to 0.59; 12 studies, 2298 participants; Botero
Aguirre 2015).
There is insuFicient evidence to confidently challenge or concur
with current clinical guidelines on duration of maintenance therapy
(Wheat 2007).
One systematic review that investigated the eFects of early versus
late ART in participants with coexisting HIV and cryptococcal
meningitis found the RR for development of IRIS to be 3.56 (95%
CI 0.51 to 25.02, 2 RCTs). The authors graded this evidence as very-
low certainty due to imprecision, risk of bias, and indirectness
indicating that they had little confidence in the eFect estimate. This
is consistent with the certainty of our findings for this outcome
although the eFect size of our included study was considerably
smaller (RR 0.43, 95% CI 0.04 to 4.82; 1 study, 10 participants).
This study also concluded that the risk of death appeared to
be higher with early ART, leading to World Health Organization
recommendations that treatment should be deferred for four to six
weeks (Eshun-Wilson 2018).
A U T H O R S '   C O N C L U S I O N S
Implications for practice
Liposomal amphotericin B appears to be a better choice
compared to deoxycholate amphotericin B for treating progressive
disseminated histoplasmosis in people with HIV. Fluconazole
appears unsuitable for induction or maintenance.
Implications for research
As there is very low-certainty evidence to inform other treatment
choices, we recommend further prospective research. A priority
question is whether in people with a clinical and immunological
response to therapy, maintenance antifungal therapy can be safely
discontinued earlier than 12 months. A further question is when is
the optimal time to start ART, and in what circumstances the risk of
IRIS may be higher? The high and varying costs of appropriate oral
antifungal agents make these questions more pertinent.
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Characteristics of included studies [ordered by study ID]
 
Study characteristics
Methods RCT
Participants 282 people with AIDS-related OIs (TB excluded), 85% male
78 African-American; 91 Hispanic; 18 from South Africa
10 with HIV + PDH
ACTG-A5164, 2009 
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241 ART-naive at study entry
Interventions Early ART (< 14 days, median 12 days)
Deferred ART (≥ 28 days, median 45 days) after start of OI treatment
Outcomes Primary: composite: 3 ordered categories:
• death/AIDS progression• no progression HIV VL ≥ 50 copies/mL• no progression HIV VL < 50 copies/mL
For ALL participants there was no statistically significant difference in the composite outcome between
early and deferred ART groups.
Secondary: AIDS progression/death; CD4 count at 24/48 weeks; HIV VL < 50% at 48 weeks, safety para-
meters including IRIS.
Death/AIDS progression in ALL participants
Favours early treatment
Deaths in people with histoplasmosis in early ART group: 1/7
Deaths in people with histoplasmosis in deferred ART group: 0/3
Safety: IRIS; lab adverse events Grades 2–4; clinical adverse events Grades 2–4
Age Median 38 years
Setting USA including Puerto Rico, ZAF
Disease severity Median CD4+ T cell count 29 cells/µL
Notes NCT00055120, ACTG A5164
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random sequence generated by central computer using permuted blocks
within Strata. Neither block size nor treatment assignments to other sites were
public.
Allocation concealment
(selection bias)
Unclear risk No details provided in protocol or included study.
Blinding of participants
and personnel (perfor-
mance bias)
All outcomes
High risk Protocol stated that for arm B (deferred ART), no study-provided drugs were
to be provided initially, hence blinding of participants and personnel was not
possible.
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Primary outcome was a composite endpoint of survival and VL. Detection bias
was unlikely.
Incomplete outcome data
(attrition bias)
All outcomes
Low risk Equal numbers withdrew without primary endpoint data in each study arm.
Details provided.
ACTG-A5164, 2009  (Continued)
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Selective reporting (re-
porting bias)
Low risk Reported outcomes were consistent with protocol.
ACTG-A5164, 2009  (Continued)
 
 
Study characteristics
Methods Single arm trial
Participants 42 (after dAmB induction) participants enrolled; 1 excluded after enrolment as diagnosis not con-
firmed.
Interventions ITRA 200 mg BD for prevention of relapse (maintenance)
Outcomes Relapse (clinical evaluation)
Death
Follow-up 109 weeks (range 4–134 weeks)
Age Mean 33 (range 16–50) years
Setting USA
Disease severity Not stated
Notes 2/42 participants relapsed
ACTG084, 1992 
 
 
Study characteristics
Methods Single arm trial
Participants 59 people with PDH in induction phase
46 people in maintenance phase
96% male
65% white and non-Hispanic people
Diagnosis based on clinical findings and laboratory evidence, including stains of tissues or body fluids,
positive cultures, or detection of Histoplasma capsulatum antigen in blood or urine.
People receiving rifampicin therapy were excluded.
Participants were allowed to receive amphotericin 1.5 mg/kg prior to induction with ITRA.
Interventions Induction phase: ITRA 300 mg BD for 3 days then 200 mg BD for 12 weeks
Maintenance phase: ITRA dose reduced to 200 mg OD if induction serum levels were at least 4 µg/mL at
week 8 or 200 mg BD if blood concentrations were lower.
Outcomes Death
ACTG120, 1992 
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Response to therapy: defined as resolution of clinical signs and symptoms of histoplasmosis.
Adverse events.
Age Mean 33 (range 16–68) years
Setting USA
Disease severity People with severe disease excluded. Defined as PO2 < 60 mmHg, SBP < 90 mmHg, or CNS histoplasmo-
sis
Notes Response to therapy: 50/59 induction phase. Of 9 failures, 2 died; 6 responded to AmB; 1 lost to fol-
low-up.
Relapse of histoplasmosis infection: 2/46 participants at median follow-up of 87 weeks. 1 due to poor
adherence and 1 to concurrent use of rifampicin.
Toxicity: 5/46 participants discontinued treatment
Mortality: 24/46 (included participants who discontinued treatment before death). Median survival
time from start of maintenance estimated at 79 weeks. 1-year survival rate estimated at 73%.
ACTG120, 1992  (Continued)
 
 
Study characteristics
Methods Single arm trial
Participants 49 people with PDH according to the revised protocol
Interventions Induction: FCN 1200 mg on first day, then 600 mg OD for 8 weeks
Maintenance: FCN 200 mg OD for ≥ 1 year
Following revision of protocol due to high failure rate (10/20)
Induction: FCN 1600 mg on first day, then 800 mg OD for 12 weeks
Maintenance: 400 mg OD for 1 year
Outcomes "Treatment response"
Induction: 36/49 (73.5%) participants responded at 12 weeks; 28 of these had resolution of signs/symp-
toms and negative cultures; 8 had clinical response but cultures missing/not done
7/49 failed treatment: 1 died histoplasmosis and pneumocystis around day 3
Maintenance: 11/36 participants relapsed. Median time on maintenance was 30 weeks. 10/11 had
blood cultures, 8/10 were positive
1/36 participants withdrew due to drug toxicity
Age Mean 36 (range not stated) years
Setting USA
Disease severity Mild to moderate
ACTG174, 1994 
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Notes Study terminated early due to relatively high relapse rate (compared to earlier ITRA trial)
ACTG174, 1994  (Continued)
 
 
Study characteristics
Methods Prospective cohort study
Participants 46, 43 people with PDH
Interventions ITRA (dosing not stated) (32/41 participants)
dAmB (22/41 participants)
lAmB (7/41 participants)
Outcomes All-cause mortality at 3 months postdiagnosis of histoplasmosis
Age Mean 38 (range not stated) years
Setting USA
Disease severity Mild to severe
Notes All-cause mortality at 3 months postdiagnosis of histoplasmosis was 18/46 participants.
Mortality data not reported by treatment regimen.
Baddley 2008 
 
 
Study characteristics
Methods Prospective cohort study
Participants 82 people with PDH
Interventions ITRA 400 mg OD (60 participants)
AmB 0.7 mg/kg/day (22 participants)
Outcomes Mortality
Age Mean 38 (range 19–68) years
Setting GUF
Disease severity Mild to severe
Notes Early death: defined as death within 30 days of initiation of antifungal treatment
Severe histoplasmosis: 12/15 participants died; dAmB 8/12, ITRA 4/12
Non-severe histoplasmosis: 6/67 participants died; dAmB 2/6, ITRA 4/6
Couppié 2004 
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First episode histoplasmosis; histoplasmosis confirmed by ≥ 1/3 methods; HIV confirmed; on antifungal
treatment for histoplasmosis; > 15 years
17% receiving ART. Severe histoplasmosis was defined as either shock that required treatment with va-
sopressors or respiratory failure that required mechanical ventilation.
Couppié 2004  (Continued)
 
 
Study characteristics
Methods Prospective cohort study
Participants 32 people living with HIV with documented histoplasmosis and ≥ 12 months of antifungal maintenance
therapy
97% male
Interventions Discontinuation of antifungal therapy for PDH
Outcomes Relapse after 1 year: 0/32
Age Mean 40 (range 22–68) years
Setting USA
Disease severity Median CD4 count at baseline 289 cells/m3
Notes Aim: to assess the safety of stopping maintenance therapy for disseminated histoplasmosis among
people living with HIV after response to ART.
At study entry, participants discontinued maintenance therapy for disseminated histoplasmosis.
The median duration of antifungal maintenance therapy before study enrolment was 34 months.
Median follow-up 24 months
Goldman 2004 
 
 
Study characteristics
Methods RCT
Participants 81 people with PDH, 88% male
52% African American, 15% Hispanic
Interventions lAmB (55 participants)
dAmB (26 participants)
Outcomes Efficacy: "Clinical success" (defined as a maximum daily temperature < 37.8 °C for 72 hours; no increase
in severity of signs, symptoms, or laboratory abnormalities attributable to histoplasmosis; and the resolu-
tion of ≥ 1 of the signs or symptoms of histoplasmosis that qualified the patient for enrolment in the trial).
73 participants evaluated for efficacy in ITT analysis
Johnson 2002 
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Clinical success in 45/51 lAmB vs 14/22 dAmB
Safety: early discontinuation
77 participants evaluated for safety in ITT analysis
Early discontinuation: 1/53 (2%) lAmB vs 2/24 (8%) dAmB
Nephrotoxicity: 5/53 (9%) lAmB vs 9/24 (37%) dAmB
Death: 1/53 (2%) lAmB (Staphylococcus aureus) vs 3/24 (12%) dAmB (progression of histoplasmosis)
Age Mean 33 (range 16–68) years
Setting USA
Disease severity Moderate to severe
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Authors reported randomization in blocks. Details of method of randomization
not provided.
Allocation concealment
(selection bias)
Low risk Closed envelopes.
Blinding of participants
and personnel (perfor-
mance bias)
All outcomes
Low risk Authors reported that participants received the intervention and comparator
by intravenous infusion "in a blinded fashion". It is possible that both partici-
pants and personnel were blinded.
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Clinical and mycological outcomes were predetermined. These included ob-
jective components including temperature and laboratory findings.
Incomplete outcome data
(attrition bias)
All outcomes
Low risk Reasons reported for missing data. Proportion of data missing from each
group was similar.
Selective reporting (re-
porting bias)
Low risk No protocol cited; however, reported outcomes were consistent with trial
aims.
Johnson 2002  (Continued)
 
 
Study characteristics
Methods Retrospective cohort study
Participants 56 people with HIV and PDH
Interventions ITRA/VORI/POSA (24 participants)
AmB (32 participants)
Luckett 2015 
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Outcomes Overall and histoplasmosis-related mortality, relapse, and treatment failure
Age Mean 42 (range 26–74) years
Setting USA
Disease severity Mild to severe
Notes Death not reported by treatment regimen
Triazole failure: 4/24 participants
Luckett 2015  (Continued)
 
 
Study characteristics
Methods Single arm trial (pilot)
Participants 22 people with PDH; 17 received maintenance treatment
95% male
Interventions Induction: all received dAmB 0.5–1.0 mg/kg (22 participants)
Initial intensive/maintenance:
Group 1
dAmB 1 g (7 participants) then weekly infusions 50–80 mg to 2000 mg cumulatively then indefinite
twice weekly infusions of 50–80 mg
Group 2
dAmB 2g (9 participants) then weekly infusions of 80 mg
dAmB 2g (1 participant) course then ketoconazole.
Outcomes Induction: dAmB < 1 g, 5 participants: 2 participants died before treatment; 1 died early in treatment; 2
died from other causes.
dAmB > 1 g, 17 participants: 13 survived → maintenance phase dAmB; 1 survived → maintenance keto-
conazole; 1 died histoplasmosis relapse; 2 died from other causes.
Initial intensive/maintenance:
Group 1:
6/7 survived at study end without clinical or laboratory evidence of relapse; 1/7 died of unrelated
cause.
Group 2:
7/9 survived at study end; 1 died of histoplasmosis relapse; 1/9 died of unrelated cause.
Median follow-up 14 months (range 2–23 months)
Age Mean 35 (range 22–57) years
Setting USA
McKinsey 1989 
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Disease severity Not stated
Notes Findings suggested that, although immediate treatment of histoplasmosis in people living with HIV
favoured higher dose of dAmB, during the remainder of induction there appeared to be little difference
between 1 g and 2 g regimens.
McKinsey 1989  (Continued)
 
 
Study characteristics
Methods Retrospective cohort study
Participants People living with HIV within a cohort formed from 3 major hospitals in French Guiana from 1 January
1997 to 30 September 2017.
Interventions ART initiation
Outcomes IRIS cases were classified as: 1. certain, case-definition fulfilled; 2. probable, relevant case with ≥ 1
case-definition criteria missing; or 3. non-IRIS, data missing, or not sufficient to conclude.
Age Mean 40.5 (SD 7.0) years
Setting GUF
Disease severity Not stated, lAmB used as proxy indicator for severe histoplasmosis.
Notes All episodes of histoplasmosis within 6 months of ART initiation.
Melzani 2020 
 
 
Study characteristics
Methods Retrospective cohort study
Participants 68 participants; 32 with PDH, 36 with penicilliosis
29 with HIV + PDH
Interventions AmB 0.7 mg/kg/day for 30 participants with PDH, duration not specified
ITRA 400 mg/day for 3 months; 200 mg/day thereafter for 27/32 participants with PDH
Outcomes Death: 3/32 participants
Relapse: 0/27 participants (median follow-up 9.5 months)
Age 33 (SD 7) years
Setting THA
Disease severity Not stated
Notes Outcomes not disaggregated by HIV status.
Mootsikapun 2006 
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Study characteristics
Methods Retrospective cohort study
Participants 97 people with PDH
38/97 participants in discontinued group (ITRA < 1 year) (A)
59/97 participants in continued group (ITRA > 1 year) (B)
Interventions ITRA for < 1 year
ITRA for > 1 year
Outcomes Relapse
Age Mean: 37 years in group A, 40 years in group B (range not stated)
Setting USA
Disease severity Mild to severe
Notes Relapsed: 0/38 participants in group A; 21/59 participants in group B.
Relapse defined as clinical and laboratory confirmation > 3 months after initial therapy.
Adherence to antifungal and ART was determined by the physicians' assessment and HIV RNA levels.
Adherence: 87% in group A vs 39% in group B; P ≤ 0.0001
Follow-up: median 49 (range 12–170) months
Myint 2014 
 
 
Study characteristics
Methods Retrospective cohort study
Participants 26 people with PDH who were followed up after discharge (from 80 hospitalized participants)
Interventions ITRA 200 mg OD (20 participants)
dAmB twice/week (6 participants)
Duration: until CD4 count > 150 cells/μL
Outcomes Not stated
Age Mean 36 (range 18–60) years
Setting ARG
Disease severity Not stated
Notes  
Negroni 2017 
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Study characteristics
Methods Retrospective cohort study
Participants 82 people with PDH
Interventions FCN at physician determined doses
Outcomes Relapse
Age Not stated
Setting USA
Disease severity Not stated
Notes  
Norris 1994 
 
 
Study characteristics
Methods Retrospective cohort study
Participants 16 people with PDH. 14 men
Interventions AmB 1 mg/kg/day up to 1 g followed by oral itraconazole 400 mg/day or FCN 200 mg/day
Outcomes Death, clinical relapse
Age Mean 28 (range 20–36) years
Setting Argentina
Disease severity Baseline CD4 count < 50 cells/µL (11 participants)
Notes  
Pietrobon 2004 
 
 
Study characteristics
Methods Prospective cohort study
Participants 14 people living with HIV with disseminated cutaneous histoplasmosis
Interventions ITRA 200 mg BD (4 participants)
AmB 0.5–1 mg/kg/day (7 participants)
Outcomes Death
Ramdial 2002 
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Clinical success
Age Mean 28 (range 3–41) years
Setting ZAF
Disease severity Not stated
Notes Follow-up: 32 months
Death: 5/14; 3 died before treatment started; 1 died day 1 in ITRA group; 1 died day 2 in AmB group
Clinical success: 9/14
Induction: 6/9 ITRA; 3/9 dAmB
Maintenance: 7/9 ITRA; 2/9 dAmB
Ramdial 2002  (Continued)
AmB: amphotericin B; ART: antiretroviral therapy; BD: twice daily; CNS: central nervous system; dAmB: deoxycholate amphotericin
B; FCN: fluconazole; IRIS: immune reconstitution inflammatory syndrome; ITRA: itraconazole; ITT: intention to treat; lAmB: liposomal
amphotericin B; OD: once daily; OI: opportunist infection; PDH: progressive disseminated histoplasmosis; PO2: partial pressure of oxygen;
POSA: posaconazole; RCT: randomized controlled trial; RNA: ribonucleic acid; SBP: systolic blood pressure; SD: standard deviation; TB:
tuberculosis; VL: viral load; VORI: voriconazole.
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Assi 2007 Retrospective cohort study, unable to extract data to inform our objectives.
Borges 1997 Retrospective cohort study, only 9 participants received antifungal therapy.
Boulougoura 2019 Conference abstract reporting incidence
Brilhante 2012 Retrospective cohort study, unable to extract data to inform our objectives: authors indicated high
failure rate with AmB, but did not elaborate on formulation, or upon disease severity.
Casariego 1997 Retrospective cohort study, unable to extract data to inform our objectives: authors stated similar
efficacy for ITRA and AmB, but no numerators or denominators given.
Chaiwarith 2013 Randomized controlled trial. Unable to extract data to inform our objectives. Authors reported 2
participants with histoplasmosis in secondary prophylaxis group but no details given on their med-
ication type or duration.
Crabtree-Ramírez 2016 Prospective cohort study, unable to extract data specific to PDH to inform our objectives.
Cunha 2007 Retrospective cohort study, unable to extract data to inform our objectives: authors stated that 3
participants were treated with oral ITRA, and switched to AmB due to poor response.
Damasceno 2013 Retrospective cohort study. Authors did not report drug doses, course durations, or disease severi-
ty.
Damasceno-Escoura 2020 Retrospective cohort study. Reports percentages of patients treated with different approaches, but
not outcomes.
Dismukes 1992 Prospective trial, included only 1 participant with HIV and histoplasmosis.
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Study Reason for exclusion
Falci 2015 Retrospective cohort study of haematological toxicities associated with AmB formulation. Unable
to extract data specific to HIV and PDH.
Gerber 1995 Retrospective cohort study. Unable to extract data to inform our objectives as authors did not re-
port HIV subgroup outcomes.
Gopalakrishnan 2012 Retrospective cohort study, only included 4 participants with PDH and HIV. Unable to extract data
to inform our objectives as authors did not report HIV subgroup outcomes.
Gutierrez 2005 Retrospective cohort study. Authors did not report drug doses, course durations, or disease severi-
ty.
Huber 2008 Retrospective cohort study. Authors did not report outcomes by type of therapy.
Karimi 2002 Retrospective cohort study. Authors did not report outcomes by drug doses, course durations, or
disease severity.
Lopez Daneri 2016 Retrospective cohort study. Authors did not report outcomes by drug doses, course durations, or
disease severity.
Mata-Essayag 2008 Retrospective cohort study. Authors were able to collect data on treatment in only 72/158 partici-
pants.
McKinsey 1996 Single arm trial of FCN for histoplasmosis. People with HIV were excluded.
Meng 2016 Retrospective cohort study. Conference abstract only, unable to extract data to inform our objec-
tives.
Messina 2018 Retrospective cohort study. Authors did not report outcomes by treatment regimen.
Mora 2008 Retrospective cohort study. Authors did not report outcomes by treatment regimen.
Nacher 2014 Prospective cohort study. Authors did not report outcomes by treatment regimen.
Negroni 1997 Retrospective cohort study. Authors did not report outcomes by treatment regimen.
Negroni 2004 Retrospective cohort study reporting on discontinuation of secondary prophylaxis after restoration
of CD4 count. Authors did not report treatment durations, therefore, unable to include.
Nightingale 1990 Retrospective cohort study, reporting survival following a stated regimen of AmB in the pre-ART
era. Unable to extract outcomes to inform our objectives.
Salzman 1988 Retrospective cohort study. Details on treatment regimens for PDH not provided. Details on HIV
status not reported. Participants were described as at risk of AIDS.
Samayoa 2017 Prospective cohort study. Authors did not report outcomes by treatment regimen.
Santos 1998 Retrospective cohort study. Authors reported good initial response to treatment but no data pro-
vided on follow-up. 1 person with histoplasmosis.
Silva 2017 Retrospective cohort study. Authors did not report outcomes by treatment regimen.
Subramanian 2005 Retrospective cohort study, included only 4 participants with HIV and PDH.
Thompson 2016 Single arm prospective trial of isavuconazole. Included 4 participants with PDH. They did not ap-
pear to have HIV/AIDS.
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Study Reason for exclusion
Tobon 2005 Retrospective cohort study. Authors did not report outcomes by treatment regimen.
Wheat 1992 Retrospective cohort study. Outcome was surrogate marker rather than clinical response.
Wheat 2018 Retrospective cohort study. Outcome data not available for HIV subgroup, or by treatment arm. Re-
ported similar mortality between induction therapy with azoles and induction therapy with AmB
formulations.
AmB: amphotericin B; ART: antiretroviral therapy; FCN: fluconazole; ITRA: itraconazole; PDH: progressive disseminated histoplasmosis.
 
Characteristics of studies awaiting classification [ordered by study ID]
 
Methods Randomized open comparative multicentre study
Participants People with blastomycosis or histoplasmosis
Interventions Intravenous itraconazole vs amphotericin B
Outcomes Not reported
Notes Information sought unsuccessfully from databases, registries, citation searching, and clinical ex-
perts.
NCT00002159 
 
Characteristics of ongoing studies [ordered by study ID]
 
Study name Randomized Trial of Liposomal Amphotericin B for Histoplasmosis in AIDS Patients
Methods Prospective randomized non-comparative multicenter open label trial of induction therapy with
LAmB for DH in AIDS patients
Participants The sample size planned is 99 patients of both sexes, older than 18 years
Interventions three study arms:
(i) single IV dose of 10 mg/kg of L-AmB;
(ii) single IV dose of 10 mg/kg of L-AmB on day 1, followed by 5 mg/kg of L-AmB on day 3;
(iii) IV dose of 3 mg/kg of L-AmB for 2 weeks.
Outcomes Primary Outcome Measures
1. Clinical response
2. Weight stability
3. Blood Pressure
4. Blood oxygen level
Starting date Not yet recruiting
Contact information Alessandro C. Pasqualotto. acpasqualotto@hotmail.com
Pasqualotto 2019 
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Notes -
Pasqualotto 2019  (Continued)
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Liposomal amphotericin B (lAmB) versus deoxycholate amphotericin B (dAmB)
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1.1 Clinical success 1 80 Risk Ratio (M-H, Fixed, 95% CI) 1.46 [1.01, 2.11]
1.2 Death 1 77 Risk Ratio (M-H, Random, 95% CI) 0.15 [0.02, 1.38]
1.3 Safety outcomes 1   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.3.1 Infusion-related toxicity 1 77 Risk Ratio (M-H, Fixed, 95% CI) 0.39 [0.22, 0.69]
1.3.2 Nephrotoxicity 1 77 Risk Ratio (M-H, Fixed, 95% CI) 0.25 [0.09, 0.67]
1.3.3 Drug discontinuation 1 77 Risk Ratio (M-H, Fixed, 95% CI) 0.23 [0.02, 2.38]
 
 
Analysis 1.1.   Comparison 1: Liposomal amphotericin B (lAmB) versus
deoxycholate amphotericin B (dAmB), Outcome 1: Clinical success
Study or Subgroup
Johnson 2002 (1)
Total (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 2.01 (P = 0.04)
Test for subgroup differences: Not applicable
lAmB
Events
45
45
Total
55
55
dAmB
Events
14
14
Total
25
25
Weight
100.0%
100.0%
Risk Ratio
M-H, Fixed, 95% CI
1.46 [1.01 , 2.11]
1.46 [1.01 , 2.11]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours lAmB Favours dAmB
Footnotes
(1) Denominators are 55 patients randomised to lAmB, and 25 randomised to dAmB, excluding one patient who died before treatment in the dAmB arm.
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Analysis 1.2.   Comparison 1: Liposomal amphotericin B (lAmB)
versus deoxycholate amphotericin B (dAmB), Outcome 2: Death
Study or Subgroup
Johnson 2002 (1)
Total (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 1.68 (P = 0.09)
Test for subgroup differences: Not applicable
lAmB
Events
1
1
Total
53
53
dAmB
Events
3
3
Total
24
24
Weight
100.0%
100.0%
Risk Ratio
M-H, Random, 95% CI
0.15 [0.02 , 1.38]
0.15 [0.02 , 1.38]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours lAmB Favours dAmB
Footnotes
(1) Denominators are safety population, all those receiving at least one dose.
 
 
Analysis 1.3.   Comparison 1: Liposomal amphotericin B (lAmB) versus
deoxycholate amphotericin B (dAmB), Outcome 3: Safety outcomes
Study or Subgroup
1.3.1 Infusion-related toxicity
Johnson 2002 (1)
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 3.25 (P = 0.001)
1.3.2 Nephrotoxicity
Johnson 2002 (1)
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 2.76 (P = 0.006)
1.3.3 Drug discontinuation
Johnson 2002 (1)
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 1.24 (P = 0.22)
Test for subgroup differences: Chi² = 0.72, df = 2 (P = 0.70), I² = 0%
lAmB
Events
13
13
5
5
1
1
Total
53
53
53
53
53
53
dAmB
Events
15
15
9
9
2
2
Total
24
24
24
24
24
24
Weight
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Risk Ratio
M-H, Fixed, 95% CI
0.39 [0.22 , 0.69]
0.39 [0.22 , 0.69]
0.25 [0.09 , 0.67]
0.25 [0.09 , 0.67]
0.23 [0.02 , 2.38]
0.23 [0.02 , 2.38]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours lAmB Favours dAmB
Footnotes
(1) Denominators are safety population, all those receiving at least one dose.
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Comparison 2.   Early antiretroviral therapy (ART) versus deferred ART
Outcome or subgroup title No. of
studies
No. of par-
ticipants
Statistical method Effect size
2.1 Immune reconstitution inflammatory syn-
drome
1 10 Risk Ratio (M-H, Fixed, 95% CI) 0.43 [0.04, 4.82]
 
 
Analysis 2.1.   Comparison 2: Early antiretroviral therapy (ART) versus
deferred ART, Outcome 1: Immune reconstitution inflammatory syndrome
Study or Subgroup
ACTG-A5164, 2009
Total (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
Early ART
Events
1
1
Total
7
7
Deferred ART
Events
1
1
Total
3
3
Weight
100.0%
100.0%
Risk Ratio
M-H, Fixed, 95% CI
0.43 [0.04 , 4.82]
0.43 [0.04 , 4.82]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours early ART Favours deferred ART
 
 
A D D I T I O N A L   T A B L E S
 
Studies at critical risk of bias outcomes: death, relapse of histoplasmosis
Study Review ob-
jective
Domain Comment
McKinsey
1989
1 and 2 Confounding Confounding domains were not controlled for. No report of ART use, CD4 counts, or
clinical condition of participants. Rationale for selection of treatment regimen not
described.
Couppié
2004
1 Participant
selection
Selection of intervention was made by the treating physician. As more severely ill
participants were more likely to get AmB than ITRA selection was strongly related to
the outcome.
Ramdial
2002
1 Confounding Confounders not addressed with respect to treatment regimens. Descriptive ac-
count provided of management of participants without detail on severity of condi-
tions, comedications, or comorbidities. No information provided on time to treat-
ment or duration of treatment.
Baddley
2008
2 Confounding Logistic regression used to determine association of variables with mortality includ-
ing potential confounders, age, and race. Antifungal treatment data were not in-
cluded in regression or reported in detail per participant. Authors reported 32/41
participants received ITRA, 22/41 dAmB, and 7/41 lAmB. Switches between med-
ications were not reported. Authors reported 29 participants received ITRA after
AmB. Denominator not reported. 8/13 participants who died were receiving an AmB
preparation and 5/13 receiving ITRA. Time of transition from AmB to azole not re-
ported.
Myint 2014 2 Confounding Physician determined discontinuation of maintenance therapy may have been influ-
enced by prognostic factors that were not controlled for. Multiple logistic regression
Table 1.   Table of studies at critical risk of bias overall (ROBINS-I): disease-related outcomes 
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used to determine variables associated with relapse; however, assignment to treat-
ment arms were based on clinical assessment and viral load. 'Adherence to therapy'
not defined. Unclear if this referred to ART, ITRA, or both. No evidence of adjustment
for time-varying confounding.
Negroni 2017 2 Confounding Comorbidity and comedications were not reported or controlled for. Outcome data
were not linked to disease severity. Outcomes not reported by drug regimen. Treat-
ment regimens varied by drug and duration. There were drug switches.
Norris 1994 2 Confounding Authors reported no specific criteria to select participants for intervention. Criteria
included unavailability of ITRA and preference for oral therapy. Intervention group
determined by treating physicians who also evaluated clinical evidence of relapse
and side effects. Severity of HIV, comorbidities and comedication were not reported.
Pietrobon
2004
2 Confounding For outcome 'relapse of histoplasmosis': follow-up periods not reported. Duration
of ITRA or FCN not reported. Switches between regimens not reported. Concurrent
medication not reported. No statistical methods to control for confounding report-
ed.
For outcome 'death': this study can be considered to be at 'serious risk of bias'. No
use of ART during treatment period. Comorbidities mentioned but unclear whether
all relevant co morbidities studied. Severity of PDH not reported. No report of statis-
tical methods to control for confounders. ≥ 1 known important domain was not ap-
propriately measured or controlled for. Given the very small numbers, we have not
reported further details in synthesis.
Table 1.   Table of studies at critical risk of bias overall (ROBINS-I): disease-related outcomes  (Continued)
For details of risk of bias assessments see Appendix 3.
AmB: amphotericin B; ART: antiretroviral therapy; dAmB: deoxycholate amphotericin B; FCN: fluconazole; ITRA: itraconazole; lAmB:
liposomal amphotericin B.
 
 
Bias Authors' judge-
ment
Support for judgement
Random sequence
generation
Unclear risk Authors reported randomizations in blocks. Details of method of randomization not
provided
Allocation conceal-
ment
Low risk Closed envelopes
Blinding of partici-
pants and personnel
Low risk Authors reported that participants received the intervention and comparator by in-
travenous infusion "in a blinded fashion". It is possible that both participants and
personnel were blinded.
Blinding of outcome
assessment
Low risk Clinical and mycological outcomes were predetermined. These included objective
components including temperature and laboratory findings.
Incomplete outcome
data
Low risk Reasons reported for missing data. Proportion of data missing from each group was
similar.
Selective reporting Low risk No protocol cited; however, reported outcomes are consistent with trial aims.
Table 2.   Risk of bias Johnson 2002 
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Bias Authors' judge-
ment
Support for judgement
Random sequence
generation
Low Random sequence was generated by central computer using permuted blocks within
strata. Neither block size nor treatment assignments to other sites were public.
Allocation conceal-
ment
Unclear No details provided in protocol or included study.
Blinding of partici-
pants and personnel
High Protocol stated that for arm B (deferred ART), no study-provided drugs were to be
provided initially hence blinding of participants and personnel was not possible.
Blinding of outcome
assessment
Low Primary outcome was a composite endpoint of survival and viral load. Detection bias
was unlikely.
Incomplete outcome
data
Low Equal numbers withdrew without primary endpoint data in each study arm. Details
provided for these participants.
Selective reporting Low Reported outcomes were consistent with protocol.
Table 3.   Risk of bias ACTG-A5164, 2009 
 
 
Studies at serious risk of bias outcomes: death, relapse of histoplasmosis
Study Review ob-
jective
Domain(s) Comment
ACTG120,
1992
1 and 2 Confound-
ing; partici-
pant selec-
tion; inter-
vention clas-
sification
Severity of HIV; severity of PDH and comorbidities were not controlled for using ap-
propriate statistical methodology. ART use at baseline of an earlier phase of the tri-
al reported: those who responded to the intervention (ITRA) in the induction phase
were selected for the intervention in the maintenance phase: participants started
intervention at various doses and had reductions in dose made at variable intervals.
While this was likely to have been informed by ITRA blood levels that were being
monitored, detailed data were not provided per participant.
ACTG174,
1994
1 and 2 Confound-
ing; partici-
pant selec-
tion
At 3 months, protocol was revised and treatment regimen amended. Analyses were
performed on participants who received the revised protocol (higher doses of FCN).
Severity and management of HIV was not reported or controlled with appropriate
statistical methods: selection into the maintenance arm of the study was related to
the effect of the intervention in the induction phase.
Luckett 2015 1 Interven-
tion classifi-
cation; out-
come mea-
surement
No information about dose, frequency, and timing of interventions. Information was
collected retrospectively. Treatment failure outcome was based on clinician judge-
ment only. This was likely to favour switch from azole to amphotericin.
ACTG084,
1992
2 Confounding Severity of HIV infection and ART use were not controlled for with appropriate sta-
tistical methods.
Goldman
2004
2 Participant
selection
Start of intervention varied – participants enrolled after a range of 14–81 months of
antifungal therapy. Unclear how many eligible people were not enrolled.
Mootsikapun
2006
2 Confound-
ing; partici-
≥ 1 known important domain was not appropriately measured or controlled for: de-
tails of disease severity, comedications and comorbidities not provided for 27 par-
ticipants discharged from hospital: maintenance therapy was commenced in those
Table 4.   Table of studies at serious risk of bias overall (ROBINS-I): disease-related outcomes 
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pant selec-
tion
who responded to initial treatment on amphotericin B. Timing of start of mainte-
nance therapy was not reported. Selection into this part of the study was related to
the intervention.
Melzani 2020 3 Confounding ART was discontinued in 2/22 participants at the physician's decision; 2/22 due to
patient choice. In unmasking group (14 participants), 10/14 received lAmB and 4/14
received ITRA. Paradoxical group (8 participants) physicians continued ART and
ITRA for 6/8. Rationale for treatment choices not reported. Appropriate statistical
measures to control for confounding were not reported. ≥ 1 known important do-
main was not appropriately measured or controlled for.
Table 4.   Table of studies at serious risk of bias overall (ROBINS-I): disease-related outcomes  (Continued)
For details of risk of bias assessment see Appendix 3.
ART: antiretroviral therapy; FCN: fluconazole; ITRA: itraconazole; lAmB: liposomal amphotericin B; PDH: progressive disseminated
histoplasmosis.
 
 
Early ART compared with deferred ART for PDH in HIV
Patient or population: adults with HIV and progressive disseminated histoplasmosis
Settings: endemic areas
Intervention: induction therapy with triazoles
Comparison: induction therapy with amphotericin B formulations
Outcomes Narrative summary Certainty of the evi-
dence
(GRADE)
Comments
Treatment
success
No RCTs make direct comparisons of amphotericin B and triazoles. Treat-
ment success of triazoles (other than fluconazole) were 83% and 85% in the
2 studies which reported them.
⊕⊝⊝⊝
Very low a,b
—
ART: antiretroviral therapy; PDH: progressive disseminated histoplasmosis; RCT: randomized controlled trial.
Table 5.   Additional summary 1: amphotericin B formulations versus azoles 
aDowngraded two levels for serious imprecision. The CIs are wide due to small numbers of participants.
bDowngraded one level for serious indirectness. No studies report direct comparisons.
 
 
Early ART compared with deferred ART for PDH in HIV
Patient or population: adults with HIV and progressive disseminated histoplasmosis
Settings: endemic areas
Intervention: early ART (< 14 days)
Comparison: late ART (> 14 days)
Out-
comes
Illustrative risks Relative effect
(95% CI)
No of partici-
pants
(studies)
Certainty of the
evidence
(GRADE)
Comments
Table 6.   Additional summary 2: early versus deferred ART 
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IRIS 1/3 partic-
ipantsa
1/7 partic-
ipantsa
RR 0.43
(0.04 to 4.82)
10
(1 study)
⊕⊝⊝⊝
Very low b,c
We do not know if early ART
increases the risk of IRIS in
people with HIV and PDH.
ART: antiretroviral therapy; IRIS: immune reconstitution inflammatory syndrome; PDH: progressive disseminated histoplasmosis;
RCT: randomized controlled trial; RR: risk ratio.
Table 6.   Additional summary 2: early versus deferred ART  (Continued)
a1/3 people with histoplasmosis in deferred ART arm developed histoplasma IRIS (day 47). 1/7 people with histoplasmosis in early ART
arm developed hepatitis C IRIS (day 14).
bDowngraded two levels for serious imprecision. The CI was wide.
cDowngraded one level for serious indirectness. The trial only included 10 participants with histoplasmosis and the case definitions were
not stated.
 
 
A P P E N D I C E S
Appendix 1. Detailed search strategies
Cochrane Central Register of Controlled Trials Issue 3 of 12, March 2020
#1 MeSH descriptor: [HIV] explode all trees
#2 MeSH descriptor: [HIV Infections] explode all trees
#3 Hiv OR hiv-1 OR hiv-2* OR hiv1 OR hiv2 OR hiv infect* OR human immunodeficiency virus OR human immunedeficiency virus
OR human immuno-deficiency virus OR human immune-deficiency virus OR ((human immun*) AND (deficiency virus )) OR acquired
immunodeficiency syndrome OR acquired immunedeficiency syndrome OR acquired immuno-deficiency syndrome OR acquired immune-
deficiency syndrome OR ((acquired immun*) AND (deficiency syndrome))
#4 #1 or #2 or #3
#5 MeSH descriptor: [Histoplasma] explode all trees
#6 MeSH descriptor: [Histoplasmosis] explode all trees
#7 histoplasm*
#8 #5 or #6 or #7
#9 #4 and #8
PubMed (MEDLINE)
 
Search set Search terms
1 ((HIV Infections[MeSH] OR HIV[MeSH] OR (Hiv OR hiv-1 OR hiv-2* OR hiv1 OR hiv2 OR hiv infect* OR
human immunodeficiency virus OR human immunedeficiency virus OR human immuno-deficien-
cy virus OR human immune-deficiency virus OR ((human immun*) AND (deficiency virus )) OR ac-
quired immunodeficiency syndrome OR acquired immunedeficiency syndrome OR acquired im-
muno-deficiency syndrome OR acquired immune-deficiency syndrome OR ((acquired immun*)
AND (deficiency syndrome)) Field: Title/Abstract
2 "Histoplasma"[Mesh] OR "Histoplasmosis"[Mesh] or Histoplasm* Field: Title/Abstract
3 1 and 2
4 "Antifungal Agents"[Mesh]
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5 "Amphotericin B"[Mesh]) OR amphotericin Field: Title/Abstract
6 "Itraconazole"[Mesh]) OR itraconazole Field: Title/Abstract
7 4 or 5or 6
8 3 and 7
9 "Randomized Controlled Trial" [Publication Type] OR "Controlled Clinical Trial" [Publication Type]
10 randomized or placebo or randomly or trial or groups Field: Title/Abstract
11 drug therapy [Subheading]
12 "Interrupted Time Series Analysis"[Mesh]
13 "Controlled Before-After Studies"[Mesh
14 “time series” Field: Title/Abstract
15 "cross-over studies"[MeSH] or crossover or cross-over Field: Title/Abstract
16 "longitudinal studies"[MeSH]
17 Longitudinal or cohort* Field: Title/Abstract
18 "Systematic Review" [Publication Type]
19 metaanalysis or meta-analysis or “systematic review” Field: Title/Abstract
20 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18
21 8 and 20
  (Continued)
 
Embase 1947-Present, updated daily
Search Strategy:
--------------------------------------------------------------------------------
1 HIV infection.mp. or HIV Infections/
2 exp HIV/ or Acquired Immunodeficiency Syndrome/
3 (Hiv or hiv-1 or hiv-2* or hiv1 or hiv2 or hiv infect* or human immunodeficiency virus or human immunedeficiency virus or human
immuno-deficiency virus or human immune-deficiency virus or (human immun* and deficiency virus) or acquired immunodeficiency
syndrome or acquired immunedeficiency syndrome or acquired immuno-deficiency syndrome or acquired immune-deficiency syndrome
or (acquired immun* and deficiency syndrome)).mp.
4 aids.mp. or acquired immune deficiency syndrome/
5 1 or 2 or 3 or 4
6 histoplasma.mp. or Histoplasma/
7 histoplasmosis.mp. or histoplasmosis/
8 6 or 7
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9 5 and 8
10 antifungal agents.mp. or antifungal agent/
11 itraconazole.mp. or itraconazole/
12 amphotericin B/ or Amphotericin B.mp.
13 10 or 11 or 12
14 9 and 13
15 randomized controlled trial/ or controlled clinical trial/
16 (randomized or placebo or randomly or trial or groups).mp
17 "time series".mp. or time series analysis/
18 (controlled before and aLer).mp.
19 crossover procedure/
20 cohort analysis/ or prospective study/ or cohort.mp.
21 longitudinal study.mp. or longitudinal study/
22 systematic review.mp. or "systematic review"/
23 (metaanalysis or meta-analysis).mp.
24 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
25 14 and 24
26 9 and 24
27 25 or 26
Science Citation Index Expanded (SCI-EXPANDED) Conference Proceedings Citation Index-Science (CPCI-S) and BIOSIS Previews
(all from Web of Science)
 
# 9 #8 AND #5
# 8 #7 OR #6
# 7 TOPIC: (antifungal*)
# 6 TOPIC: (itraconazole or amphotericin)
# 5 #4 AND #3
# 4 TOPIC: (histoplasma or histoplasmosis)
# 3 #2 OR #1
# 2 TOPIC: (Hiv OR hiv-1 OR hiv-2* OR hiv1 OR hiv2 OR hiv infect* OR human immunodefi-
ciency virus OR human immunedeficiency virus OR human immuno-deficiency virus OR
human immune-deficiency virus OR ((human immun*) AND (deficiency virus )) OR ac-
quired immunodeficiency syndrome OR acquired immunedeficiency syndrome OR ac-
quired immuno-deficiency syndrome OR acquired immune-deficiency syndrome OR ((ac-
quired immun*) AND (deficiency syndrome)))
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# 1   TOPIC: (HIV OR AIDS OR "human immunodeficiency virus" or "acquired immunodeficien-
cy syndrome" or AIDS)
  (Continued)
 
WHO International Clinical Trials Registry Platform (WHO ICTRP), Clinicaltrials.gov, and ISRCTN registry
histoplasm* and HIV*
Appendix 2. ROBINS-I methodology
Risk of bias: ROBINS-I
Target trial(s)
To determine bias, as defined by systematic diFerences between a non-randomized study and a hypothetical pragmatic randomized trial,
we formulated the following target trial (Sterne 2016).
Design: individually randomized
Participants: HIV-positive children, adolescents, and adults with a clinical diagnosis of progressive disseminated histoplasmosis.
 
Objective Intervention Comparisons
1. Induction Liposomal amphotericin B (3.0 mg/kg daily) for 1–2
weeks
Lipid complex amphotericin B
Deoxycholate amphotericin B
Other antifungal agents
2. Maintenance Oral antifungal treatment for < 12 months Oral antifungal treatment for ≥ 12 months
3. ART Early initiation (within 4 weeks of commencing anti-
fungal therapy)
Delayed initiation (> 4 weeks after starting antifungal
treatment
 
 
The aim was to assess the eFect of assignment to the intervention, that is, we assessed studies on the basis of intention to treat.
Judgements were guided by the use of signalling questions at domain level using ROBINS-I methodology (Sterne 2016).
Confounding domains relevant to all or most studies that were determined a priori informed by current literature and clinical expertise.
Table A a priori confounding domains
 
Confounding domains relevant to all or most studies Cointerventions that could be different between intervention
groups and that could impact on outcomes
Severity of PDH ART at time of PDH diagnosis
Severity of HIV (CD4 count) Supportive therapy
Comorbidities and comedications —
ART: antiretroviral therapy; PDH: progressive disseminated histoplasmosis
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Severity of progressive disseminated histoplasmosis (PDH) and HIV were considered likely to influence clinicians to favour intravenous
therapy including liposomal amphotericin B. Comorbidities and comedications were also determined to influence medical management.
In particular, use of medications which may interact with azoles may cause a clinician to favour use of amphotericin during induction
therapy.
Overall risk of bias judgements were determined using the following table from detailed guidance on the use of ROBINS-I. Sterne JAC,
Higgins JPT, Elbers RG, Reeves BC and the development group for ROBINS-I. Risk Of Bias In Non-randomized Studies of Interventions
(ROBINS-I): detailed guidance, updated 12 October 2016. Available from www.riskofbias.info (accessed 4 June 2019).
Table B guidance on ROBINS-I judgements
 
Response option Criteria
Low risk of bias (the study is comparable to a well-performed random-
ized trial).
The study is at low risk of bias for all domains.
Moderate risk of bias (the study appears to provide sound evidence
for a non-randomized study but cannot be considered comparable to a
well-performed randomized trial).
The study is at low or moderate risk of bias for all do-
mains.
Serious risk of bias (the study has some important problems). The study is at serious risk of bias in ≥ 1 domain, but not at
critical risk of bias in any domain.
Critical risk of bias (the study is too problematic to provide any useful
evidence and should not be included in any synthesis).
The study is at critical risk of bias in ≥ 1 domain.
No information on which to base a judgement about risk of bias. There is no clear indication that the study is at serious or
critical risk of bias and there is a lack of information in ≥ 1
key domains of bias.
Sterne 2016.
 
 
Table C ROBINS-I. Assessments of non-randomized studies
 
Study: Luckett 2015. Outcome: treatment success
Confounding
domains
Measured
variable(s)
Is there evidence that controlling for
this variable was unnecessary?
Is the confounding domain mea-
sured validly and reliably?
OPTIONAL Is
failure to ad-
just for this
variable ex-
pected to
favour inter-
vention or
comparator
Severity of PDH Severe,
moderate,
and mild ill-
ness were
defined
No Yes —
Severity of HIV CD4 count
and viral
No Yes —
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load re-
ported
Comorbidities
and comedica-
tions
Not report-
ed
No Not measured Comorbidities
likely to influ-
ence clinicians
to favour lipo-
somal ampho-
tericin.
Cointerventions Is there evidence that controlling for this cointer-
vention was unnecessary?
Is presence of this cointervention likely to favour
outcomes in the intervention or comparator?
ART at time of
PDH diagnosis
No, remains important cointervention. 27% on ART
prior to study. 1/3 adherent.
Favour intervention
Supportive ther-
apy
Reported level of clinical care (e.g. ICU care) Favour intervention
Bias domain Signalling
questions
Comments Risk of bias
judgement
Bias due to con-
founding
1.1–1.8 Authors described severity of PDH, and reported median and range of CD4
count. Authors did not report any comorbidities or comedications. Baseline
characteristics of participants in azole and amphotericin groups not reported.
Authors did not report use of appropriate statistical methods to control for im-
portant baseline confounding. Rationale for treatment choice in azole and am-
photericin groups not reported. There was insufficient information to judge
bias due to confounding.
No informa-
tion
Bias in partici-
pant selection
2.1–2.5 No evidence that selection into the study based on participant characteristics
observed after intervention. Authors did not report the time between start of
follow-up and start of intervention.
Moderate
Bias in classifica-
tion of interven-
tion
3.1–3.3 No information about dose, frequency, and timing of interventions. Informa-
tion was collected retrospectively.
Serious
Bias due to de-
viations from in-
tended interven-
tion
4.1–4.6 No evidence of deviations from interventions. No comment on whether pa-
tients not on ART were commenced on ART. No measure of adherence to anti-
fungal therapy.
No informa-
tion
Bias due to miss-
ing data
5.1–5.5 No information regarding loss to follow-up. No informa-
tion
Bias in measure-
ment of out-
comes
6.1–6.4 For mortality outcome, unlikely to display measurement bias. For treatment
failure outcome, based on clinician judgement only, likely to favour switch
from azole to amphotericin.
Serious
Bias in selection
of reported re-
sult
7.1–7.3 Limited analysis. No informa-
tion
Overall bias SERIOUS
  (Continued)
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Study: Mootsikapun 2006.Outcome 1: inhospital mortality
Confounding do-
mains
Measured
vari-
able(s)
Is there evidence that controlling
for this variable was unnecessary?
Is the confounding domain mea-
sured validly and reliably?
OPTIONAL
Is failure to
adjust for
this variable
expected to
favour in-
tervention
or compara-
tor
Severity of PDH Not re-
ported
No No information provided —
Severity of HIV Not re-
ported
No No information provided —
Comorbidities and
comedications
None re-
ported
No No information provided —
Cointerventions Is there evidence that controlling for this coint-
ervention was unnecessary?
Is presence of this cointervention likely to favour
outcomes in the intervention or comparator?
ART at time of PDH di-
agnosis
No —
Supportive therapy No —
Bias domain Sig-
nalling
questions
Comments Risk of bias
judgement
Bias due to confound-
ing
1.1–1.8 ≥ 1 known important domain was not appropriately measured or controlled
for. Details of disease severity, comedications, and comorbidities not provid-
ed for the 3 inhospital deaths.
Serious
Bias in participant se-
lection
2.1–2.5 Authors reported data on 29 participants who received AmB 0.7 mg/kg/day.
Data not provided on alternate treatment regimens or time to treatment;
however, since all participants received the same treatment, it is probable
that selection into the study was not related to the outcome.
Moderate
Bias in classification of
intervention
3.1–3.3 Comparison was between disease populations not intervention groups. Inter-
vention status was well defined.
Moderate
Bias due to deviations
from intended inter-
vention
4.1–4.6 Deviations were not reported. Important cointerventions were not reported. No informa-
tion
Bias due to missing
data
5.1–5.5 Data reported on inhospital deaths likely to be reasonably complete. Low
Bias in measurement
of outcomes
6.1–6.4 The outcome measure was unlikely to be influenced by knowledge of the in-
tervention.
Low
Bias in selection of re-
ported result
7.1–7.3 There is too little information to make a judgement on bias in reporting in
this retrospective review of medical records.
No informa-
tion
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Overall bias SERIOUS
  (Continued)
 
 
Study: Mootsikapun 2006. Outcome 2: relapse on maintenance itraconazole. Median follow-up 22 months (1–75 months)
Confounding do-
mains
Measured
vari-
able(s)
Is there evidence that controlling for
this variable was unnecessary?
Is the confounding domain measured
validly and reliably?
OPTION-
AL Is fail-
ure to ad-
just for
this vari-
able ex-
pected to
favour in-
terven-
tion or
compara-
tor
Severity of PDH Not re-
ported
No — —
Severity of HIV Not re-
ported
No — —
Comorbidities and
comedications
None re-
ported
No — —
Cointerventions Is there evidence that controlling for this cointer-
vention was unnecessary?
Is presence of this cointervention likely to favour
outcomes in the intervention or comparator?
ART at time of
PDH diagnosis
No —
Supportive thera-
py
No —
Bias domain Sig-
nalling
questions
Comments Risk
of bias
judge-
ment
Bias due to con-
founding
1.1–1.8 ≥ 1 known important domain was not appropriately measured or controlled for: de-
tails of disease severity, comedications, and comorbidities not provided for 27 par-
ticipants discharged from hospital.
Serious
Bias in participant
selection
2.1–2.5 Maintenance therapy was commenced in those who responded to initial treatment
on AmB. Timing of start of maintenance therapy was not reported. Selection into
this part of the study was related to the intervention.
Serious
Bias in classifica-
tion of interven-
tion
3.1–3.3 Authors reported that participants who responded to treatment with AmB received
oral itraconazole 400 mg/day for 3 months then 200 mg/day afterwards. Median
follow-up for participants was 22 (range 1–75) months. Although response to treat-
ment was likely to have been a clinical decision bias intervention, status appeared
to be adequately defined. Range of duration of follow-up was wide.
Moderate
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Bias due to devia-
tions from intend-
ed intervention
4.1–4.6 Cointerventions were not reported. Deviations from practice not reported. Moderate
Bias due to miss-
ing data
5.1–5.5 Data obtained from medical records from a 7-year period. Range of follow-up was 1–
75 months. Outcome data not provided on individual participants. There was insuf-
ficient information to base a judgement about risk of bias for this domain.
No infor-
mation
Bias in measure-
ment of outcomes
6.1–6.4 Retrospective data collection. Unlikely to be assessor bias in participant eligibility
for maintenance therapy.
Low
Bias in selection of
reported result
7.1–7.3 Authors reported no relapse in participants who had itraconazole as long-term ther-
apy; however, range of duration of follow-up was wide.
Moderate
Overall bias SERIOUS
  (Continued)
 
 
Study: Myint 2014.Outcome: relapse of histoplasmosis
Confounding domains Measured vari-
able(s)
Is there evidence that con-
trolling for this variable
was unnecessary?
Is the confounding do-
main measured validly
and reliably?
OPTIONAL
Is failure to
adjust for
this variable
expected to
favour in-
tervention
or compara-
tor
Severity of PDH Defined and re-
ported
No — —
Severity of HIV Defined and re-
ported
No — —
Comorbidities and comedica-
tions
ART adherence
monitored with
CD4 count and HIV
RNA load
No — —
Cointerventions Is there evidence that controlling for this coint-
ervention was unnecessary?
Is presence of this cointervention likely
to favour outcomes in the intervention
or comparator?
ART at time of PDH diagnosis 34% in each group (12/35, 19/56) —
Supportive therapy Reported —
Bias domain Signalling ques-
tions
Comments Risk of bias
judgement
Bias due to confounding 1.1–1.8 Physician determined discontinuation of maintenance
therapy may have been influenced by prognostic factors
that were not controlled for. Multiple logistic regression
used to determine variables associated with relapse; how-
Critical
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ever, assignment to treatment arms was based on clinical
assessment and viral load. 'Adherence to therapy' not de-
fined. Unclear if this referred to ART, ITRA, or both. No evi-
dence of adjustment for time-varying confounding.
Bias in participant selection 2.1–2.5 — —
Bias in classification of interven-
tion
3.1–3.3 — —
Bias due to deviations from in-
tended intervention
4.1–4.6 — —
Bias due to missing data 5.1–5.5 — —
Bias in measurement of out-
comes
6.1–6.4 — —
Bias in selection of reported re-
sult
7.1–7.3 — —
Overall bias CRITICAL
  (Continued)
 
 
Study: Myint 2014.Outcome: death
Confounding domains Measured variable(s) Is there evidence
that controlling
for this variable
was unneces-
sary?
Is the confound-
ing domain mea-
sured validly and
reliably?
OPTIONAL Is fail-
ure to adjust for
this variable ex-
pected to favour
intervention or
comparator
Severity of PDH Defined and reported No Yes —
Severity of HIV Defined and reported No Yes —
Comorbidities and comedications ART adherence moni-
tored with CD4 count
and HIV RNA load
No Yes —
Cointerventions Is there evidence that controlling for this
cointervention was unnecessary?
Is presence of this cointervention like-
ly to favour outcomes in the interven-
tion or comparator?
ART at time of PDH diagnosis No —
Supportive therapy No —
Bias domain Signalling questions Comments Risk of bias
judgement
Bias due to confounding 1.1–1.8 Participants in the physician continued
therapy group are likely to have been
Critical
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more ill and therefore at higher risk of
death.
Bias in participant selection 2.1–2.5    
Bias in classification of intervention 3.1–3.3    
Bias due to deviations from intended in-
tervention
4.1–4.6    
Bias due to missing data 5.1–5.5    
Bias in measurement of outcomes 6.1–6.4    
Bias in selection of reported result 7.1–7.3    
Overall bias CRITICAL
  (Continued)
 
 
Study: Negroni 2017.Outcome: response to maintenance therapy
Confounding domains Measured variable(s) Is there evidence
that controlling
for this variable
was unneces-
sary?
Is the confound-
ing domain
measured valid-
ly and reliably?
OPTIONAL
Is failure to
adjust for
this variable
expected to
favour in-
tervention
or compara-
tor
Severity of PDH Not defined No    
Severity of HIV CD4 count No    
Comorbidities and comedica-
tions
17.5% on ART at baseline
41% of participants discharged from
hospital continued with follow-up of
ART and maintenance therapy.
Authors reported use of AmB in partic-
ipants who were more ill and in those
on medication likely to interact with
itraconazole such as rifampicin sug-
gesting there could have been comor-
bid TB.
No — —
Cointerventions Is there evidence that controlling for this cointervention
was unnecessary?
Is presence of this cointerven-
tion likely to favour outcomes
in the intervention or compara-
tor?
ART at time of PDH diagnosis No —
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Supportive therapy No —
Bias domain Signalling questions Comments Risk of bias
judgement
Bias due to confounding 1.1–1.8 Comorbidity and comedications were
not reported or controlled for. Out-
come data were not linked to disease
severity. Outcomes not reported by
drug regimen. Treatment regimens
varied by drug and duration. There
were drug switches.
Critical
Bias in participant selection 2.1–2.5 — —
Bias in classification of interven-
tion
3.1–3.3 — —
Bias due to deviations from in-
tended intervention
4.1–4.6 — —
Bias due to missing data 5.1–5.5 — —
Bias in measurement of out-
comes
6.1–6.4 — —
Bias in selection of reported re-
sult
7.1–7.3 — —
Overall bias CRITICAL
  (Continued)
 
 
Study: Norris 1994.Outcome: relapse of histoplasmosis
Confounding domains Measured variable(s) Is there evidence
that controlling for
this variable was
unnecessary?
Is the confounding
domain measured
validly and reliably?
OPTIONAL
Is failure to
adjust for
this variable
expected to
favour in-
tervention
or compara-
tor
Severity of PDH Not reported. All participants had
completed induction treatment for
histoplasmosis before study start-
ed. Successful induction deter-
mined clinically. Fungal cultures
not performed in all patients to
confirm success of induction.
— — —
Severity of HIV No measured variable reported. — — —
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Comorbidities and comedica-
tions
Multiple drug regimens used prior
to intervention.
HIV management not reported.
— — —
Cointerventions Is there evidence that controlling for this cointervention
was unnecessary?
Is presence of this cointervention
likely to favour outcomes in the in-
tervention or comparator?
ART at time of PDH diagnosis No —
Supportive therapy No —
Bias domain Signalling questions Comments Risk of bias
judgement
Bias due to confounding 1.1–1.8 Authors reported no specific criteria to se-
lect participants for intervention. Criteria in-
cluded unavailability of ITRA and preference
for oral therapy. Intervention group deter-
mined by treating physicians who also evalu-
ated clinical evidence of relapse and adverse
effects. Severity of HIV, comorbidities, and
comedication were not reported.
Critical
Bias in participant selection 2.1–2.5 — —
Bias in classification of inter-
vention
3.1–3.3 — —
Bias due to deviations from
intended intervention
4.1–4.6 — —
Bias due to missing data 5.1–5.5 — —
Bias in measurement of out-
comes
6.1–6.4 — —
Bias in selection of reported
result
7.1–7.3 — —
Overall bias CRITICAL
  (Continued)
 
 
Study: Pietrobon 2004. Outcome: mortality
Confounding do-
mains
Measured vari-
able(s)
Is there evidence that control-
ling for this variable was unnec-
essary?
Is the confounding domain
measured validly and reliably?
OPTION-
AL Is fail-
ure to ad-
just for
this vari-
able ex-
pected to
favour in-
tervention
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or com-
parator
Severity of PDH Not defined or re-
ported.
No No —
Severity of HIV Authors reported
11/16 participants
with histoplasmosis
had CD4 count < 50
cells/μL
No Yes —
Comorbidities and
comedications
Authors report-
ed none of partici-
pants were receiv-
ing ART. Study pop-
ulation was 16. Co-
morbidities men-
tioned but not sys-
temically.
No No —
Cointerventions Is there evidence that controlling for this cointerven-
tion was unnecessary?
Is presence of this cointervention likely to
favour outcomes in the intervention or com-
parator?
ART at time of PDH
diagnosis
No —
Supportive therapy No —
Bias domain Signalling ques-
tions
Comments Risk of
bias judge-
ment
Bias due to con-
founding
1.1–1.8 No use of ART during treatment period. Comorbidities mentioned
but unclear whether all relevant comorbidities studied. Severity of
PDH not reported. No report of statistical methods to control for con-
founders. ≥ 1 known important domain was not appropriately mea-
sured or controlled for.
Serious
Bias in participant
selection
2.1–2.5 Drug treatment for the initial phase provided for all participants – all
received AmB. Time to commencement of treatment not reported. Da-
ta reported were retrospective analyses of medical records of patients
with HIV and opportunistic infections.
No infor-
mation
Bias in classification
of intervention
3.1–3.3 Intervention for management of acute phase was well defined. Low
Bias due to devia-
tions from intended
intervention
4.1–4.6 Deviations not reported. No infor-
mation
Bias due to missing
data
5.1–5.5 Data were reasonably complete. Low
Bias in measurement
of outcomes
6.1–6.4 Measurement of mortality outcome unlikely to be influenced by
knowledge of intervention received.
Low
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Bias in selection of
reported result
7.1–7.3 Descriptive retrospective study. No protocol; however, there was no
indication of selection of the cohort for analysis and reporting on the
basis of the result.
Moderate
Overall bias Serious
  (Continued)
 
 
Study: Pietrobon 2004.Outcome: relapse of histoplasmosis
Confounding do-
mains
Measured variable(s) Is there evidence that control-
ling for this variable was un-
necessary?
Is the confounding domain
measured validly and reli-
ably?
OPTION-
AL Is fail-
ure to ad-
just for
this vari-
able ex-
pected to
favour in-
terven-
tion or
compara-
tor
Severity of PDH Not defined or reported. No No —
Severity of HIV Authors reported 8/12 par-
ticipants with histoplas-
mosis had CD4 count < 50
cells/μL
No Yes —
Comorbidities and
comedications
Authors reported none
of participants were re-
ceiving ART. Study popula-
tion was 16. This included
participants with various
opportunistic infections.
Coinfection with Crypto-
coccus neoformans report-
ed in 1 participant; howev-
er, authors did not specify
if this participant also had
histoplasmosis.
No No —
Cointerventions Is there evidence that controlling for this cointervention
was unnecessary?
Is presence of this cointervention likely
to favour outcomes in the intervention or
comparator?
ART at time of
PDH diagnosis
No —
Supportive thera-
py
No —
Bias domain Signalling questions Comments Risk
of bias
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judge-
ment
Bias due to con-
founding
1.1–1.8 Follow-up periods not reported. Duration of ITRA or FCN not report-
ed. Switches between regimens not reported. Concurrent medica-
tion not reported. No statistical methods to control for confounding
reported.
Critical
Bias in participant
selection
2.1–2.5 Participants treated with maintenance therapy would have re-
sponded to initial treatment. Time to commencement of mainte-
nance therapy not reported. Insufficient information to judge if
start of follow-up and start of intervention coincided for most par-
ticipants.
No infor-
mation
Bias in classifica-
tion of interven-
tion
3.1–3.3 Commencement of maintenance therapy was dependent on re-
sponse to initial therapy with AmB. Intervention status was not well
defined.
Serious
Bias due to devia-
tions from intend-
ed intervention
4.1–4.6 No reported deviations from intended intervention. No infor-
mation
Bias due to miss-
ing data
5.1–5.5 Outcome data available for all participants. Low
Bias in measure-
ment of outcomes
6.1–6.4 Relapse was not clearly defined. Time periods were not reported.
The outcome measure was subjective and assessed by assessors
aware of the intervention.
Serious
Bias in selection of
reported result
7.1–7.3 Descriptive retrospective study. No protocol; however, there was no
indication of selection of the cohort for analysis and reporting on
the basis of the result.
Moderate
Overall bias Critical
  (Continued)
 
 
Study:Baddley 2008. Outcome: all-cause mortality at 3 months postdiagnosis
Confounding domains Measured vari-
able(s)
Is there evidence that con-
trolling for this variable
was unnecessary?
Is the confounding domain
measured validly and reli-
ably?
OPTION-
AL Is fail-
ure to ad-
just for
this vari-
able ex-
pected to
favour in-
tervention
or com-
parator
Severity of PDH Clinical parameters
were defined and
laboratory confir-
mation criteria were
specified.
No — —
 
Treating progressive disseminated histoplasmosis in people living with HIV (Review)
Copyright © 2020 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
63
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Severity of HIV CD4 count and HIV
viral load
No — —
Comorbidities and comed-
ications
Among those with
previously diagnosed
HIV 21.7% reported
ART use.
No — —
Cointerventions Is there evidence that controlling for this cointer-
vention was unnecessary?
Is presence of this cointervention likely
to favour outcomes in the intervention or
comparator?
ART at time of PDH diagno-
sis
No —
Supportive therapy No —
Bias domain Signalling ques-
tions
Comments Risk of
bias judge-
ment
Bias due to confounding 1.1–1.8 Logistic regression used to determine association of variables
with mortality including potential confounders, age, and race.
Antifungal treatment data were not included in regression or
reported in detail per participant. Authors reported 32/41 par-
ticipants received ITRA, 22/41 received dAmB, 7/41 received
lAmB formulation. Switches between medications were not
reported. Authors reported 29 participants received ITRA after
AmB. Denominator not reported. 8/13 participants who died
received an AmB preparation and 5/13 received ITRA. Time of
transition from AmB to azole not reported.
Critical
Bias in participant selection 2.1–2.5 — —
Bias in classification of in-
tervention
3.1–3.3 — —
Bias due to deviations from
intended intervention
4.1–4.6 — —
Bias due to missing data 5.1–5.5 — —
Bias in measurement of out-
comes
6.1–6.4 — —
Bias in selection of reported
result
7.1–7.3 — —
Overall bias Critical
  (Continued)
 
 
Study: Couppié 2004.Outcome: death within 1 month of starting antifungal treatment
Confounding
domains
Measured vari-
able(s)
Is there evidence that controlling
for this variable was unnecessary?
Is the confounding domain mea-
sured validly and reliably?
OPTION-
AL Is fail-
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ure to ad-
just for
this vari-
able ex-
pected to
favour in-
terven-
tion or
compara-
tor
Severity of PDH Severe was de-
fined as either
shock that re-
quired treatment
with vasopres-
sors or respirato-
ry failure that re-
quired mechan-
ical ventilation.
Other cases were
defined as 'non
severe'.
No 'Non-severe' included a wide range of
severity.
—
Severity of HIV CD4 count No Yes —
Comorbidities
and comedica-
tions
17.1% of partic-
ipants were tak-
ing antiretroviral
medication.
No Not enough information. —
Cointerventions Is there evidence that controlling for this cointerven-
tion was unnecessary?
Is presence of this cointervention likely to favour
outcomes in the intervention or comparator?
ART at time of
PDH diagnosis
No —
Supportive ther-
apy
No —
Bias domain Signalling ques-
tions
Comments Risk
of bias
judge-
ment
Bias due to con-
founding
1.1–1.8 Choice of first-line antifungal treatment was made by the treating physician
based on severity of histoplasmosis and renal function. Authors reported high-
er rate of mortality in participants treated with AmB than those treated with
ITRA in univariate analysis. However, as participants who were more clini-
cally ill were more likely to have been commenced on AmB by the treating
physician, authors recognized that this was a confounding factor. Appropriate
methods to control for this were not reported.
Severe
Bias in partici-
pant selection
2.1–2.5 Selection of intervention was made by the treating physician. As more severely
ill participants were more likely to get AmB than ITRA, selection was strongly
related to the outcome.
Critical
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Bias in classifica-
tion of interven-
tion
3.1–3.3 Classification of intervention status could have been affected by risk of the
outcome.
Moderate
Bias due to de-
viations from in-
tended interven-
tion
4.1–4.6 Details of treatment regimens were not provided. No infor-
mation
Bias due to miss-
ing data
5.1–5.5 Participants lost at follow-up in the first 30 days were excluded. No informa-
tion on proportion missing with respect to the outcome.
No infor-
mation
Bias in measure-
ment of out-
comes
6.1–6.4 The outcome measure was unlikely to have been influenced by knowledge of
the intervention.
Low
Bias in selection
of reported re-
sult
7.1–7.3 Prospective study that determined a priori to report death as dichotomous
variable: death within 30 days of starting antifungal treatment and no death
during the first 30 days of treatment. Data presented for both outcomes.
Low
Overall bias Critical
  (Continued)
 
 
Study: Goldman 2004. Outcome: relapse of histoplasmosis
Confounding domains Measured variable(s) Is there evidence that con-
trolling for this variable
was unnecessary?
Is the confounding do-
main measured validly
and reliably?
OPTION-
AL Is fail-
ure to ad-
just for
this vari-
able ex-
pected to
favour in-
tervention
or com-
parator
Severity of PDH Evidence of histoplasmosis
infection AND remission with
antigen concentrations <
4.1 units and negative blood
culture.
No Yes —
Severity of HIV CD4 – required to have > 150
cells/μL for study entry.
No Yes —
Comorbidities and
comedications
Required to have received
both antifungal and ART
treatment for ≥ 12 months
prior to starting trial.
No Yes —
Cointerventions Is there evidence that controlling for this cointervention
was unnecessary?
Is presence of this cointervention like-
ly to favour outcomes in the interven-
tion or comparator?
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ART at time of PDH diag-
nosis
All participants were required to be on ART at time of initia-
tion into trial.
—
Supportive therapy Not reported —
Bias domain Signalling questions Comments Risk of
bias judge-
ment
Bias due to confounding 1.1–1.8 Protocol stipulated eligibility criteria for all the con-
founding domains cited above.
Low
Bias in participant selec-
tion
2.1–2.5 Start of intervention varied – participants enrolled after
a range of 14–81 months of antifungal therapy. Unclear
how many eligible patients not enrolled.
Serious
Bias in classification of
intervention
3.1–3.3 Intervention was well-defined – discontinuation of anti-
fungal treatment
Low
Bias due to deviations
from intended interven-
tion
4.1–4.6 Regular monitoring of participants ensured that interven-
tion was delivered as intended.
Low
Bias due to missing data 5.1–5.5 Details on missing data were reported. Low
Bias in measurement of
outcomes
6.1–6.4 Relapse of histoplasmosis was clearly defined in the pro-
tocol.
Low
Bias in selection of re-
ported result
7.1–7.3 Outcome of interest was determined in the protocol and
reported.
Low
Overall bias Serious
  (Continued)
 
 
Study: Ramdial 2002.Outcome: death at 32 months
Confounding domains Measured vari-
able(s)
Is there evidence that
controlling for this vari-
able was unnecessary?
Is the confounding domain
measured validly and reli-
ably?
OPTIONAL Is
failure to ad-
just for this
variable ex-
pected to
favour inter-
vention or
comparator
Severity of PDH Organ involve-
ment
No Not according to standard
classification
—
Severity of HIV CD4 count No Yes —
Comorbidities and comedica-
tions
Not reported No — —
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Cointerventions Is there evidence that controlling for this
cointervention was unnecessary?
Is presence of this cointervention likely to
favour outcomes in the intervention or com-
parator?
ART at time of PDH diagnosis No. ART use was not reported. —
Supportive therapy No. Not reported. —
Bias domain Signalling
questions
Comments Risk of bias
judgement
Bias due to confounding 1.1–1.8 Confounders not addressed with respect to treatment
regimens. Descriptive account provided of management
of participants without detail on severity of conditions,
comedications, or comorbidities. No information provid-
ed on time to treatment or duration of treatment.
Critical
Bias in participant selection 2.1–2.5 Some of these cases are likely to have been Emer-
gomyces.
—
Bias in classification of interven-
tion
3.1–3.3 — —
Bias due to deviations from in-
tended intervention
4.1–4.6 — —
Bias due to missing data 5.1–5.5 — —
Bias in measurement of out-
comes
6.1–6.4 — —
Bias in selection of reported re-
sult
7.1–7.3 — —
Overall bias Critical
  (Continued)
 
 
Study: McKinsey 1989. Outcome: 2-year survival
Confounding domains Measured vari-
able(s)
Is there evidence
that controlling for
this variable was un-
necessary?
Is the confound-
ing domain mea-
sured validly and
reliably?
OPTIONAL Is
failure to adjust
for this vari-
able expected
to favour inter-
vention or com-
parator
Severity of PDH Not defined or re-
ported
No No —
Severity of HIV Not defined or re-
ported
No No —
Comorbidities and comedications Not reported No No —
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Cointerventions Is there evidence that controlling for this
cointervention was unnecessary?
Is presence of this cointervention like-
ly to favour outcomes in the interven-
tion or comparator?
ART at time of PDH diagnosis No. No report of ART use. —
Supportive therapy No. Not described. —
Bias domain Signalling ques-
tions
Comments Risk of bias
judgement
Bias due to confounding 1.1–1.8 Confounding domains were not controlled
for. Rationale for selection of treatment regi-
men not described. No report of ART use, CD4
counts, or clinical condition of participants.
Critical
Bias in participant selection 2.1–2.5 — —
Bias in classification of intervention 3.1–3.3 — —
Bias due to deviations from intended in-
tervention
4.1–4.6 — —
Bias due to missing data 5.1–5.5 — —
Bias in measurement of outcomes 6.1–6.4 — —
Bias in selection of reported result 7.1–7.3 — —
Overall bias CRITICAL
  (Continued)
 
 
Study: McKinsey 1989. Outcome: relapse of histoplasmosis
Confounding domains Measured vari-
able(s)
Is there evidence
that controlling for
this variable was un-
necessary?
Is the confound-
ing domain mea-
sured validly and
reliably?
OPTIONAL Is
failure to adjust
for this vari-
able expected
to favour inter-
vention or com-
parator
Severity of PDH Not defined or re-
ported
No No —
Severity of HIV Not defined or re-
ported
No No —
Comorbidities and comedications Not reported No No —
Cointerventions Is there evidence that controlling for this
cointervention was unnecessary?
Is presence of this cointervention like-
ly to favour outcomes in the interven-
tion or comparator?
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ART at time of PDH diagnosis No. No report of ART use. —
Supportive therapy No. Not reported. —
Bias domain Signalling ques-
tions
Comments Risk of bias
judgement
Bias due to confounding 1.1–1.8 Confounding domains were not controlled
for. Rationale for selection of treatment regi-
men not described. No report of ART use, CD4
counts or clinical condition of participants
Critical
Bias in participant selection 2.1–2.5 — —
Bias in classification of intervention 3.1–3.3 — —
Bias due to deviations from intended in-
tervention
4.1–4.6 — —
Bias due to missing data 5.1–5.5 — —
Bias in measurement of outcomes 6.1–6.4 — —
Bias in selection of reported result 7.1–7.3 — —
Overall bias Critical
  (Continued)
 
 
Study: ACTG084, 1992.Outcome: response to therapy (prevention of relapse)
Confounding domains Measured variable(s) Is there evidence that con-
trolling for this variable
was unnecessary?
Is the confounding domain
measured validly and reli-
ably?
OPTIONAL
Is failure to
adjust for
this variable
expected to
favour in-
tervention
or compara-
tor
Severity of PDH Participants required
to have been treated
successfully for con-
firmed disseminated
histoplasmosis within
6 weeks of enrolment.
No Unsure —
Severity of HIV CD4 No Yes —
Comorbidities and
comedications
Protocol stipulated
parameters on comor-
bidities and comedica-
tions.
No Probably —
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Cointerventions Is there evidence that controlling for this cointer-
vention was unnecessary?
Is presence of this cointervention likely
to favour outcomes in the intervention or
comparator?
ART at time of PDH diag-
nosis
No. Zidovudine use reported. —
Supportive therapy — —
Bias domain Signalling questions Comments Risk of bias
judgement
Bias due to confounding 1.1–1.8 Severity of HIV infection and ART use were not controlled for
with appropriate statistical methods.
Serious
Bias in participant selec-
tion
2.1–2.5 Selection into the study may have been related to the inter-
vention and outcome. Start of follow-up and start of interven-
tion coincided for all participants.
Moderate
Bias in classification of
intervention
3.1–3.3 Intervention status was clearly defined. Low
Bias due to deviations
from intended interven-
tion
4.1–4.6 No reported deviations from usual practice. Management of
HIV not reported.
No informa-
tion
Bias due to missing data 5.1–5.5 Outcome data available for all participants. Low
Bias in measurement of
outcomes
6.1–6.4 Relapse was determined by clinical assessment, Histoplasma
c. antigen levels in urine and serum and blood cultures at pre-
determined intervals.
Low
Bias in selection of re-
ported result
7.1–7.3 Reported results are consistent with preregistered protocol. Low
Overall bias Serious
  (Continued)
 
 
Study: ACTG174, 1994. Outcome: response to therapy
Confounding
domains
Measured vari-
able(s)
Is there evidence that controlling
for this variable was unnecessary?
Is the confounding domain mea-
sured validly and reliably?
OPTION-
AL Is fail-
ure to ad-
just for
this vari-
able ex-
pected to
favour in-
terven-
tion or
compara-
tor
Severity of PDH Defined with clini-
cal and laboratory
No Yes —
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parameters includ-
ing Histoplasma
capsulatum antigen
in blood or urine.
Severity of HIV CD4 No Yes —
Comorbidities
and comedica-
tions
Comorbidities and
comedications not
clearly reported.
Exclusions includ-
ed various med-
ications, allergies,
adrenal insufficien-
cy, and pregnancy.
No — —
Cointerventions Is there evidence that controlling for this cointervention
was unnecessary?
Is presence of this cointervention likely to
favour outcomes in the intervention or com-
parator?
ART at time of
PDH diagnosis
No. Number of participants on ART at baseline was report-
ed (33%).
—
Supportive ther-
apy
No. —
Bias domain Signalling ques-
tions
Comments Risk
of bias
judge-
ment
Bias due to con-
founding
1.1–1.8 At 3 months, protocol was revised and treatment regimen amended. Analy-
ses were performed on participants who received the revised protocol
(higher doses of FCN). Severity and management of HIV was not reported or
controlled with appropriate statistical methods.
Serious
Bias in partici-
pant selection
2.1–2.5 Selection into the maintenance arm of the study was related to the effect of
the intervention in the induction phase.
Serious
Bias in classifica-
tion of interven-
tion
3.1–3.3 Intervention was well defined based on information collected at the time of
intervention.
Low
Bias due to de-
viations from in-
tended interven-
tion
4.1–4.6 The possibility of a requirement to modify the original protocol was raised
a priori. Some deviations from intervention were reported such as 3 partici-
pants who relapsed when receiving FCN 400 mg being given 800 mg prior to
successful treatment with AmB; however, there was insufficient information
reported on deviation from the intended intervention to make a judgement
in this domain.
No Infor-
mation
Bias due to miss-
ing data
5.1–5.5 Some missing data in outcome measurement. No infor-
mation
Bias in measure-
ment of out-
comes
6.1–6.4 Definition and proposed measurement of relapse were clearly defined a pri-
ori. Some cultures were missing or not done in the induction phase; howev-
er, 6/7 non-responders to induction had cultures taken.
Low
  (Continued)
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Bias in selection
of reported re-
sult
7.1–7.3 Results correspond to intended outcomes. Analysis restriction to those
treated per the revised protocol was not predetermined.
Moderate
Overall bias Serious
  (Continued)
 
 
Study: ACTG120, 1992 . Outcome: relapse of histoplasmosis – maintenance phase
Confounding do-
mains
Measured vari-
able(s)
Is there evidence that control-
ling for this variable was unnec-
essary?
Is the confounding domain mea-
sured validly and reliably?
OPTION-
AL Is fail-
ure to ad-
just for
this vari-
able ex-
pected to
favour in-
terven-
tion or
compara-
tor
Severity of PDH Defined – severe
disease excluded.
No Yes —
Severity of HIV CD4 No No. Not reported after baseline of
induction phase.
—
Comorbidities and
comedications
Participants re-
ceiving concurrent
treatment with
drugs that interact
with ITRA includ-
ing rifampin were
excluded.
No No —
Cointerventions Is there evidence that controlling for this cointerven-
tion was unnecessary?
Is presence of this cointervention likely to
favour outcomes in the intervention or com-
parator?
ART at time of PDH
diagnosis
No. ART use not reported. Median CD4 at baseline ofind-
uction phase was 29 (range 2–346) cells/μL. CD4 count at
baseline of maintenance phase was not reported.
A2—
Supportive therapy No —
Bias domain Signalling ques-
tions
Comments Risk
of bias
judge-
ment
Bias due to con-
founding
1.1–1.8 Severity of HIV; severity of PDH and comorbidities were not controlled for
using appropriate statistical methodology. ART use at baseline of an ear-
lier phase of the trial reported.
Serious
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Bias in participant
selection
2.1–2.5 Those who responded to the intervention (ITRA) in the induction phase
were selected for the intervention in the maintenance phase.
Serious
Bias in classification
of intervention
3.1–3.3 Participants started intervention at various doses and had reductions in
dose made at variable intervals. While this is likely to have been informed
by ITRA blood levels that were being monitored detailed data is not pro-
vided per participant.
Serious
Bias due to devia-
tions from intended
intervention
4.1–4.6 Data reported indicates that deviations from the intended intervention
were not beyond that expected in usual practice.
Low
Bias due to missing
data
5.1–5.5 12/46 participants withdrew from the study. Reasons reported for all. Low
Bias in measurement
of outcomes
6.1–6.4 Definition and proposed measurement of relapse were clearly defined a
priori.
Low
Bias in selection of
reported result
7.1–7.3 Reported results correspond to intended outcomes. Low
Overall bias Serious
  (Continued)
 
 
Study: ACTG120, 1992 . Outcome: relapse of histoplasmosis –induction phase
Confounding do-
mains
Measured vari-
able(s)
Is there evidence that controlling
for this variable was unnecessary?
Is the confounding domain
measured validly and reliably?
OPTION-
AL Is fail-
ure to ad-
just for
this vari-
able ex-
pected to
favour in-
terven-
tion or
compara-
tor
Severity of PDH Defined – severe
disease excluded.
No Yes —
Severity of HIV CD4 No No. Only baseline reported —
Comorbidities and
comedications
Participants re-
ceiving concurrent
treatment with
drugs that interact
with ITRA includ-
ing rifampin were
excluded.
No No. Limited data reported —
Cointerventions Is there evidence that controlling for this cointerven-
tion was unnecessary?
Is presence of this cointervention likely to
favour outcomes in the intervention or com-
parator?
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ART at time of PDH
diagnosis
No. Report 35/59 using ART at baseline. No further data
provided on HIV management.
—
Supportive therapy Those requiring intensive supportive therapy were exclud-
ed.
—
Bias domain Signalling ques-
tions
Comments Risk
of bias
judge-
ment
Bias due to con-
founding
1.1–1.8 Severity of HIV; severity of PDH and comorbidities were not controlled for
using appropriate statistical methodology.
Serious
Bias in participant
selection
2.1–2.5 Selection into the study may have been related to the intervention and
outcome as those with less severe histoplasmosis were more likely to be
selected; however, start of follow-up and intervention appear to coin-
cide.
Moderate
Bias in classification
of intervention
3.1–3.3 Data provided per participant for ITRA levels in non-responders. Detailed
data on ITRA levels not reported for remaining participants. ITRA levels
determined dose of intervention.
Serious
Bias due to devia-
tions from intended
intervention
4.1–4.6 Deviations from intended intervention were consistent with usual prac-
tice. Data reported for toxicity and clinical reasons for discontinuation of
intervention.
Low
Bias due to missing
data
5.1–5.5 Data were reasonably complete. Low
Bias in measurement
of outcomes
6.1–6.4 Outcome measures were confirmed by laboratory assessments such as
blood culture.
Low
Bias in selection of
reported result
7.1–7.3 Reported results correspond to intended outcomes. Low
Overall bias Serious
  (Continued)
 
 
Study: ACTG120, 1992.Outcome: mortality –maintenance phase
Confounding do-
mains
Measured vari-
able(s)
Is there evidence that controlling
for this variable was unnecessary?
Is the confounding domain mea-
sured validly and reliably?
OPTION-
AL Is fail-
ure to ad-
just for
this vari-
able ex-
pected to
favour in-
terven-
tion or
compara-
tor
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Severity of PDH Defined – severe
disease excluded.
No Yes —
Severity of HIV CD4 No No. Not reported after baseline of
induction phase.
—
Comorbidities and
comedications
Participants re-
ceiving concurrent
treatment with
drugs that interact
with ITRA includ-
ing rifampin were
excluded.
No No —
Cointerventions Is there evidence that controlling for this cointerven-
tion was unnecessary?
Is presence of this cointervention likely to
favour outcomes in the intervention or com-
parator?
ART at time of PDH
diagnosis
No. ART use not reported. Median CD4 at baseline ofind-
uction phase was 29 (range 2–346) cells/dL. CD4 count at
baseline of maintenance phase was not reported.
—
Supportive therapy No —
Bias domain Signalling ques-
tions
Comments Risk
of bias
judge-
ment
Bias due to con-
founding
1.1–1.8 Severity of HIV; severity of PDH and comorbidities were not controlled for
using appropriate statistical methodology. ART use at baseline of an earli-
er phase of the trial reported.
Serious
Bias in participant
selection
2.1–2.5 Participants who responded to the intervention (ITRA) in the induction
phase were selected for the intervention in the maintenance phase.
Serious
Bias in classifica-
tion of intervention
3.1–3.3 Participants started intervention at various doses and had reductions in
dose made at variable intervals. While this is likely to have been informed
by ITRA blood levels that were being monitored, detailed data were not
provided per participant.
Serious
Bias due to devia-
tions from intended
intervention
4.1–4.6 Deviations from intended intervention were consistent with usual prac-
tice. Data reported for toxicity and clinical reasons for discontinuation of
intervention.
Low
Bias due to missing
data
5.1–5.5 12/46 participants withdrew from the study. Reasons reported for all. Low
Bias in measure-
ment of outcomes
6.1–6.4 The outcome measure was unlikely to be influenced by knowledge of the
intervention received.
Low
Bias in selection of
reported result
7.1–7.3 Reported results correspond to intended outcomes. Low
Overall bias Serious
  (Continued)
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Study: ACTG120, 1992.Outcome: mortality –induction
Confounding domains Measured vari-
able(s)
Is there evidence that control-
ling for this variable was un-
necessary?
Is the confounding domain mea-
sured validly and reliably?
OPTION-
AL Is fail-
ure to ad-
just for
this vari-
able ex-
pected to
favour in-
tervention
or com-
parator
Severity of PDH Defined – severe
disease excluded
No Yes —
Severity of HIV CD4 No No. Only baseline data reported. —
Comorbidities and
comedications
Participants re-
ceiving concur-
rent treatment
with drugs that
interact with
ITRA including ri-
fampin were ex-
cluded.
No No. Limited data reported. —
Cointerventions Is there evidence that controlling for this cointer-
vention was unnecessary?
Is presence of this cointervention likely to
favour outcomes in the intervention or com-
parator?
ART at time of PDH di-
agnosis
No —
Supportive therapy No —
Bias domain Signalling ques-
tions
Comments Risk of
bias judge-
ment
Bias due to confound-
ing
1.1–1.8 Severity of HIV; severity of PDH and comorbidities were not controlled
for using appropriate statistical methodology.
Serious
Bias in participant se-
lection
2.1–2.5 Selection into the study may have been related to the intervention
and outcome as those with less severe histoplasmosis were more like-
ly to be selected; however, start of follow-up and intervention appear
to coincide.
Moderate
Bias in classification of
intervention
3.1–3.3 1 of the 2 deaths was reported to have died after 1 week of AmB. Serious
Bias due to deviations
from intended interven-
tion
4.1–4.6 Data reported indicates that deviations from the intended interven-
tion were not beyond that expected in usual practice.
Low
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Bias due to missing da-
ta
5.1–5.5 Detailed data provided for non-responders. 1/9 lost to follow-up. Low
Bias in measurement of
outcomes
6.1–6.4 The outcome measure was unlikely to be influenced by knowledge of
the intervention received.
Low
Bias in selection of re-
ported result
7.1–7.3 Reported results correspond to intended outcomes. Low
Overall bias Serious
  (Continued)
 
 
Study: Melzani 2020.Outcome: incidence paradoxical and unmasking IRIS
Confounding do-
mains
Measured variable(s) Is there evidence that control-
ling for this variable was unnec-
essary?
Is the confounding domain
measured validly and reliably?
OPTION-
AL Is fail-
ure to ad-
just for
this vari-
able ex-
pected to
favour in-
terven-
tion or
compara-
tor
Severity of PDH Severity of IRIS de-
fined. lAmB consid-
ered as proxy for
histoplasmosis-relat-
ed IRIS severity. Sever-
ity of PDH not report-
ed.
— — —
Severity of HIV CD4 and HIV viral load No Yes —
Comorbidities and
comedications
TB excluded. No infor-
mation reported on
comorbidities. ART,
antifungal, and steroid
use described. 2/22
participants received
steroids.
No Yes. Taken from medical records. —
Cointerventions Is there evidence that controlling for this cointervention
was unnecessary?
Is presence of this cointervention likely to
favour outcomes in the intervention or com-
parator?
ART at time of PDH
diagnosis
No —
Supportive therapy No. Clinical management was reported. —
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Bias domain Signalling questions Comments Risk
of bias
judge-
ment
Bias due to con-
founding
1.1–1.8 ART was discontinued in 2/22 participants at the physician's decision;
2/22 due to patient choice. In unmasking group, 10/14 participants
received lAmB and 4/14 received ITRA. Paradoxical group physicians
continued ART and ITRA for 6/8. Rationale for treatment choices not
reported. Appropriate statistical measures to control for confounding
were not reported. ≥ 1 known important domain was not appropriate-
ly measured or controlled for.
Serious
Bias in participant
selection
2.1–2.5 Information on timelines not provided. No infor-
mation
Bias in classifica-
tion of intervention
3.1–3.3 Detailed information on type, dose, and timing of interventions not re-
ported.
No infor-
mation
Bias due to devia-
tions from intended
intervention
4.1–4.6 Deviations are likely to be consistent with usual practice. Low
Bias due to missing
data
5.1–5.5 Authors reported that data were missing and files were difficult to re-
view due to poor storage conditions. Insufficient information to make
an informed judgement in this domain.
No Infor-
mation
Bias in measure-
ment of outcomes
6.1–6.4 Outcome measure was unlikely to be influenced by knowledge of the
intervention.
Low
Bias in selection of
reported result
7.1–7.3 Reported results correspond to all intended outcomes. Low
Overall bias Serious
  (Continued)
 
AmB: amphotericin B; ART: antiretroviral therapy; dAmB; deoxycholate amphotericin B; FCN: fluconazole; ICU: intensive care unit; IRIS:
immune reconstitution inflammatory syndrome; ITRA: itraconazole; lAmB: liposomal amphotericin B; PDH: progressive disseminated
histoplasmosis; RNA: ribonucleic acid; TB: tuberculosis.
Notes
Appropriate methods to control for measured confounders: stratification; regression; matching; standardization; g-estimation; and inverse
probability weighting.
Time-varying confounding – when intervention received can change over time. The eFect of interest is 'starting and adhering' (per-protocol)
NOT 'assignment to intervention' (intention to treat).
Appendix 3. Excluded studies: not eligible due to study design, but may inform PICO
Review papers (0)
We excluded reviews from our protocol, but present them in this report for completeness.
 
Review Commentary on methods Commentary on outcome
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Botero Aguirre
2015
Cochrane review, robust methods. lAmB less nephrotoxic.
Cano-Torres 2019 No protocol, registration with PROSPERO or quality as-
sessment.
Aimed to provide estimate of frequency and mor-
tality of histoplasmosis in people living with HIV on
HAART in Latin America but heterogeneity preclud-
ed aggregated estimates.
Hamill 2013 Single author, narrative drug review. No protocol, regis-
tration with PROSPERO, or quality assessment. Limited
search strategy.
lAmB safer than conventional AmB with at least
equivalent efficacy.
Hughes 2010 Details of methodology not provided. No protocol, regis-
tration with PROSPERO, or quality assessment reported.
Limited search strategy.
Azoles (except FCN) posed greatest risk of interac-
tions with ART. There was limited evidence that risk
was lower with echinocandins. Tenofovir should be
used with caution with AmB with close monitoring
of renal function advised.
Karimzadeh 2013 5 databases searched. Details of screening not provid-
ed. Language restriction. No protocol, registration with
PROSPERO, or quality assessment reported.
Coadministration of mannitol did not show any
clinically significant benefit in preventing AmB-in-
duced nephrotoxicity. Lipid formulations are clini-
cally effective and safe at preventing AmB-induced
nephrotoxicity.
Keating 2005 Single author drug profile. Posaconazole was associated with 100% success
rate in histoplasmosis.
Moen 2009 Methodology not reported in detail. Databases searched
from 1980 to 2009.No protocol, registration with
PROSPERO, or quality assessment reported.
For the treatment of confirmed invasive fungal in-
fections, liposomal AmB was more effective than
AmB and remained first-line option for empirical
therapy in people with disseminated histoplasmo-
sis.
Pan 2013 3 databases (English and Chinese) searched. Papers in-
dependently reviewed by 2 authors. No protocol or qual-
ity assessment reported.
300 cases of histoplasmosis were reported in Chi-
na from 1990 to 2011, of which 257 had PDH. Cases
had a prominent geographical distribution, mainly
in vicinity of Yangtze river.
Siberry 2013 Guideline for the prevention and treatment of oppor-
tunistic infections in HIV-exposed and HIV-infected chil-
dren. Specialists reviewed the literature for new infor-
mation since publication of the last guidelines (2009).
AmB is preferred for initial treatment of moderately
severe-to-severe infections.
Slain 2001 Therapeutic review. Included data from in vitro and pre-
clinical studies as well as Phase 2 and 3 clinical trials. 1
database searched.
Intravenous ITRA is less toxic alternative to AmB for
people with pulmonary and extrapulmonary histo-
plasmosis.
AmB: amphotericin B; ART: antiretroviral therapy; FCN: fluconazole; HAART: highly active antiretroviral therapy; ITRA: itraconazole;
lAmB: liposomal amphotericin B; PDH: progressive disseminated histoplasmosis.
  (Continued)
 
Case series or unclear study design (6–7)
We present a simple list of excluded case reports and case series which may inform PICO, but are not included in the main review due to
their design.
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Study Commentary
Armstrong 1988 Overview of the treatment of opportunistic infections in people with AIDS. Highlights lack of evi-
dence for maintenance regimens.
Assi 2006 Case series of gastrointestinal histoplasmosis. None of the patients identified had received HAART.
Barlows 1996 Case study of hypothermia following IV AmB.
Benson 2005 Guidelines for treatment of OI in HIV-infected adults and children; CDC, NIH, and HIVMA.
Bernard 1989 Case series of treatment with FCN. 1 person with histoplasmosis. Urine still positive at day 75. 20
participants. 10 people living with HIV. Did not report HIV status of the person with histoplasmosis.
Bonifaz 2009 Case series of PDH. Authors did not report any use of ART.
BSAC 1992 Treatment recommendations from British Society for Antimicrobial Chemotherapy.
Caplivski 2005 Case series. 4 participants had histoplasmosis and AIDS.
Carme 1993 Case series. 14 participants with Histoplasma duboisii seen in Congo.
Chastain 2017 Review update on epidemiology, diagnosis, and management of OIs in people living with HIV.
Del 1990 Case series; authors do not report outcomes by treatment regimen.
Ferguson-Paul 2018 Case series of disseminated histoplasmosis in paediatric kidney transplant recipients.
Ferreira 2002 Case series of participants with oral manifestations of histoplasmosis. 8/10 people living with HIV.
Gustafson 1985 Case report in letter to editor of Archives of Internal Medicine detailing failure of ketoconazole as
maintenance therapy.
Hage 2011 Antigen clearance study.
Hajjeh 2001 Case-control study to identify risk factors for histoplasmosis among people living with HIV.
Harrison 1990 Case report of 2 children. Participant 1 had AIDS and was treated successfully with AmB for induc-
tion and maintenance. Participant 2 was HIV positive and died 6 months after diagnosis.
Hostetler 1991 Review of use of ITRA in treatment of systemic fungal infections. 8 participants had histoplasmosis
and AIDS. Authors did not report outcomes by treatment regimen or detail ART.
Hung 2004 Prospective single arm. 1 or 2 participants with histoplasmosis. No data on management.
Johnson 1989 Clinical review. Comparison of case series of 64 participants with PDH and AIDS with summaries of
61 participants in published literature.
Johnson 1986 Case series. Comparison of case series of 12 cases with summaries of 20 previously reported cases.
Johnson 1988 Case series. 48 participants with PDH and AIDS. Concluded that because of the permanence of im-
munodeficiency, PDH was resistant to treatment in this population.
Kassamali 2012 Case series, some of whom may have had PDH, but insufficient data reported.
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LeMonte 2000 MICs determined to 10 clinical isolates to investigate efficacy of combined treatment with FCN and
AmB. Caution against use of FCN+AmB for treatment of histoplasmosis.
Lewin 1995 Case report.
Machado 1991 Case series of 6 people living with HIV with cutaneous-mucosal involvement of histoplasmosis.
Majluf-Cruz 1993 Case series of 3 cases with haemophagocytic syndrome associated with histoplasmosis and AIDS.
Marianelli 2014 Case report of IRIS in people living with HIV with histoplasmosis osteomyelitis.
Mashayekhi 2016 Renal transplant recipients with histoplasmosis.
Mazumder 2007 Retrospective case-control study of people living with HIV with CD4 count < 50 cells/μL and PDH. 26
cases, 42 controls. On multivariate analysis high alkaline phosphatase and weight loss were inde-
pendent predictors of PDH.
Moazeni 2009 Clinical overview of OIs in people living with HIV and AIDS.
Murphy 2015 Case series of 3 participants highlighting difficulties managing PDH in resource-limited settings
where lAmB and ITRA are not readily available.
Negroni 1990 Case series. Provided information on outcomes by treatment regimen.
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AmB: amphotericin B; ART: antiretroviral therapy; CDC: Centers for Disease Control and Prevention; FCN: fluconazole; HAART: highly
active antiretroviral therapy; HIVMA: HIV Medicine Association; IRIS: immune reconstitution inflammatory syndrome; ITRA: itraconazole;
IV: intravenous; lAmB: liposomal amphotericin B; MIC: minimal inhibitory concentration; NIH: National Institutes of Health; OI: opportunist
infection; PDH: progressive disseminated histoplasmosis.
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